ifosfamide has been researched along with Metastase in 176 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "High-dose methotrexate (HD-MTX) is recognized as an efficient component of therapy against pediatric osteosarcoma in combination with other drugs such as cisplatin (CDP), carboplatin (CBDCA), doxorubicin (ADM), etoposide (VP-16) and ifosfamide (IFO)." | 9.19 | Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( Anurathapan, U; Choeyprasert, W; Chuansumrit, A; Hongeng, S; Nartthanarung, A; Pakakasama, S; Sirachainan, N; Songdej, D, 2014) |
| "The EICESS-92 Trial compared the efficacy of cyclophosphamide and ifosfamide in patients with Ewing sarcoma." | 9.14 | Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma. ( DuBois, SG; Grier, HE, 2009) |
| "The aim of this study was to evaluate the maximum tolerated dose (MTD) and safety of the combination of non- pegylated liposomal doxorubicin (Myocet) and ifosfamide in patients with metastatic soft tissue sarcomas." | 9.14 | Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. ( Barbato, A; Bertuzzi, A; Di Comite, G; Lutman, RF; Mussi, C; Santoro, A; Stroppa, E, 2010) |
| "High-dose ifosfamide plus doxorubicin is an active regimen for all subtypes of gynecological sarcomas." | 9.12 | Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. ( Cerny, T; Dietrich, D; Fey, M; Honegger, HP; Jundt, G; Leyvraz, S; Lissoni, A; Sessa, C; Zweifel, M, 2006) |
| "This phase I study evaluated the toxicity of first-line combined pegylated liposomal doxorubicin (Caelyx) and ifosfamide in patients with advanced and/or metastatic soft tissue sarcomas." | 9.12 | Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. ( Blay, J; Christensen, TB; Daugaard, S; Hermans, C; Judson, I; Marreaud, S; Nielsen, OS; Pink, D; Reichardt, P; van Glabbeke, M, 2006) |
| "The established clinical activity of docetaxel and ifosfamide as single agents in anthracycline pre-treated breast cancer, led us to conduct a phase I-II study to define the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and clinical activity of the docetaxel+ifosfamide combination in this setting." | 9.12 | Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study. ( Gassiamis, A; Karabelis, A; Kosmas, C; Malamos, N; Mylonakis, N; Polyzos, A; Skopelitis, H; Tsakonas, G; Tsavaris, N, 2007) |
| "To study the role of single agent carboplatin chemotherapy in patients with metastatic seminoma based on the data from two randomised trials." | 9.11 | Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. ( Bokemeyer, C; Clemm, C; Gerl, A; Hartmann, JT; Horwich, A; Kanz, L; Kollmannsberger, C; Meisner, C; Oliver, T; Rückerl, CP; Schmoll, HJ; Stenning, S, 2004) |
| "The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma." | 9.10 | Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002) |
| "A prospective trial to evaluate the efficacy and toxicity of ifosfamide (IFX) and vinorelbine (VNB) in patients with prior anthracycline therapy for metastatic breast cancer (MBC) was conducted." | 9.09 | Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy. ( Aziz, Z; Qazi, S; Rehman, A, 1999) |
| "Forty-six patients were included in a phase II study to evaluate the response rate and toxicity of a combination of ifosfamide and vinorelbine in metastatic breast cancer patients previously treated with one or more regimens of chemotherapy." | 9.09 | Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy. ( Albistur, JJ; Barnadas, A; Constenla, M; Estévez, LG; Frau, A; Lizón, J; Lobo, F; Martínez, P; Méndez, M; Provencio, M; Sánchez, MJ, 1999) |
| "Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study." | 9.09 | Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001) |
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 9.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| "Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m-2 and epirubicin 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim)." | 9.08 | The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. ( Calvert, AH; Cantwell, BM; Chapman, F; Gumbrell, L; Lind, MJ; McCann, E; Middleton, I; Millward, MJ; Proctor, M; Simmonds, D, 1995) |
| "We conducted a phase I/II trial to investigate the activity of ifosfamide/carboplatin/etoposide given over 2 or 3 days (mini-ICE) to patients with anthracycline-refractory or recurrent metastatic breast cancer." | 9.08 | Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships. ( Elfenbein, GJ; Fields, KK; Perkins, JB, 1995) |
| "This study was designed to test if the activity of a phase II agent, ifosfamide, would have been underestimated if it was tested exclusively in a population of children and young adults with recurrent osteosarcoma." | 9.08 | Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. ( Ayala, AG; Cantor, AB; Ferguson, WS; Goorin, AM; Harris, MB; Holbrook, T; Link, MP; Shochat, SJ, 1995) |
| "Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity." | 9.08 | Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. ( Hartmann, LC; Ingle, JN; Krook, JE; Mailliard, JA; Wieand, HS, 1995) |
| "To determine the effectiveness and toxicity of ifosfamide chemotherapy in women with metastatic or recurrent endometrial stromal sarcomas unexposed to other chemotherapy." | 9.08 | Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. ( Blessing, JA; DiSaia, PJ; Park, R; Rosenshein, N; Sutton, G, 1996) |
| "In a randomized, phase II trial, we evaluated the effectiveness of continued chemotherapy with epirubicin/ ifosfamide versus unmaintained treatment interruption in advanced metastatic breast cancer." | 9.08 | Epirubicin and ifosfamide in metastatic breast cancer. ( Bartels, H; Becher, R; DeDycker, R; Fischedick, AR; Halabi, S; Hartwich, G; Hawig, I; Hayungs, J; Hering, KG; Hirche, H; Höfeler, H; Huhn, R; Illiger, HJ; Kloke, O; Ohl, S; Pielken, HJ; Rieche, K; Seeber, S; Szanto, J; Wolf, E, 1996) |
| "To evaluate the efficacy and toxicity of the combination of ifosfamide (IFX) and vinorelbine (VNB) as first-line chemotherapy in metastatic breast cancer (MBC)." | 9.08 | Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. ( Acuña, JM; Acuña, LA; Amato, S; Barbieri, MR; Cuevas, MA; Dominguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Ortiz, EH; Perez, JE; Rodriguez, R; Romero, AO; Sabatini, CL; Salvadori, MA; Vallejo, CT, 1996) |
| "The new combination of ifosfamide and vinorelbine was evaluated in a phase II study of patients with metastatic breast cancer." | 9.08 | Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. ( Cafiero, F; Gipponi, M; Landucci, M; Pronzato, P; Queirolo, P; Vaira, F; Vigani, A, 1997) |
| "The aim of this paper is to evaluate the activity of ifosfamide in previously treated patients with metastatic breast cancer." | 9.08 | Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. ( Esparza-Guerra, L; Holmes, FA; Hortobagyi, GN; Valero, V; Walters, RS, 1998) |
| "A combination of 5-fluorouracil (5-FU), adriamycin, and cyclophosphamide (FAC) was compared to a combination of 5-FU, adriamycin, and ifosfamide (FAI) in the treatment of metastatic breast cancer." | 9.04 | Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Hersh, EM; Hortobagyi, GN; Legha, SS; Tashima, CK; Yap, HY, 1979) |
| "This meta-analysis examines the role of ifosfamide-based combination chemotherapy in patients with advanced soft tissue sarcoma." | 8.84 | Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. ( Blackstein, M; Haynes, AE; Stys-Norman, D; Verma, S; Younus, J, 2008) |
| "A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA)." | 7.80 | Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma. ( Batschinski, K; Dervisis, NG; Kitchell, BE, 2014) |
| "We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer (MBC)." | 7.76 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. ( Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH, 2010) |
| "The efficacy of zoledronic acid (ZOL), with or without the anticancer drug ifosfamide (IFO), was tested on primary bone tumor growth using a rat-transplantable model of osteosarcoma." | 7.73 | Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. ( Blanchard, F; Charrier, C; Coipeau, P; Couillaud, S; Gouin, F; Heymann, D; Heymann, MF; Ory, B; Redini, F; Thiery, JP, 2005) |
| "Ifosfamide is a leading drug in soft tissue sarcoma therapy." | 7.70 | Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998) |
| "25 previously untreated patients with inoperable or metastatic adenocarcinoma of the oesophagus or oesophageal-gastric junction area were treated with ifosfamide 6 g/m2 over 48 hours, combined with mesna 6 g/m2." | 7.68 | Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; Tilanus, HW; van der Gaast, A, 1991) |
| "The combination of ifosfamide (IFO) and epirubicin (EPI) has been found to be an effective regimen in the treatment of metastatic tumours and shows remarkable activity in heavily pretreated breast cancer patients." | 7.68 | Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. ( Hoffmann, W; Könner, J; Migeod, F; Seeber, S; Weidmann, B, 1990) |
| "Thirty-seven patients with widely metastatic malignant melanoma were treated with one of three chemotherapy regimens, incorporating high-dose dacarbazine (DTIC)." | 7.67 | High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. ( Carr, T; Chadwick, G; Craig, P; Jones, R; Lind, M; Morgenstern, G; Thatcher, D, 1989) |
| "Ifosfamide was tested in a phase II study in 12 evaluable patients with advanced malignant melanoma." | 7.67 | Phase II study with ifosfamide in advanced malignant melanoma. ( Bajetta, E; Bonfante, V; Ferrari, L; Negretti, E, 1988) |
| "Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)." | 7.66 | [Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983) |
| "" The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle." | 6.80 | Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. ( Chou, AJ; Goodbody, CM; Magnan, H; Pratilas, CA; Riedel, E; Wexler, LH, 2015) |
| " Ifosfamide with G-CSF in combination with doxorubicin or paclitaxel achieves effective mobilization of PBPC and anti-tumor activity with minimal toxicity." | 6.69 | Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer. ( Brettell, M; Briggs, P; Chapple, P; Francis, P; Gardyn, J; Gates, P; Januszewicz, EH; Juneja, S; Millward, MJ; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Toner, GC; Wolf, M, 1999) |
| "Twenty-five patients with metastatic breast cancer were treated with ICE after failure of previous chemotherapy." | 6.69 | Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer. ( Asbury, R; Boros, L; Chang, AY; Garrow, G; Hui, L; Rubins, J, 1999) |
| "Patients with metastatic breast cancer refractory to all standard dose therapy were treated with escalating doses of mitoxantrone (45 to 105 mg/m2) and thiotepa (900 to 1,350 mg/m2) followed by autologous stem cell rescue." | 6.67 | Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. ( Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE, 1993) |
| "Doxorubicin, the most active agent for breast cancer, was studied first." | 6.39 | Paclitaxel combination therapy in the treatment of metastatic breast cancer. ( Holmes, FA, 1996) |
| "Metastases from cystosarcoma phyllodes are rare, and treatment generally is ineffective." | 6.38 | Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. ( Fisher, C; Hawkins, RE; McKinna, JA; Schofield, JB; Wiltshaw, E, 1992) |
| "Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity." | 5.37 | High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011) |
| "Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990." | 5.28 | Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. ( Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M, 1990) |
| "Ifosfamide (Z 4942) is an alkylating agent with the structure of a cyclophosphamide analog." | 5.27 | [Treatment of pain caused by metastases of reactivated prostatic cancer with ifosfamide]. ( Kawai, T; Kihara, K; Sakuramoto, T; Satomi, Y; Takeda, T, 1983) |
| "Patients with high-grade soft tissue sarcomas were treated with 2 cycles of ifosfamide, mitomycin, doxorubicin, and cisplatin plus GM-CSF subcutaneous followed by 45 Gy irradiation with concurrent 2 cycles of mitomycin, doxorubicin, and cisplatin followed by surgery +/- intraoperative radiation or brachytherapy." | 5.22 | Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively. ( Haddock, M; Mahoney, M; Maples, W; Markovic, SN; O'Connor, MI; Okuno, S; Petersen, I; Shives, T; Sim, F, 2016) |
| "High-dose methotrexate (HD-MTX) is recognized as an efficient component of therapy against pediatric osteosarcoma in combination with other drugs such as cisplatin (CDP), carboplatin (CBDCA), doxorubicin (ADM), etoposide (VP-16) and ifosfamide (IFO)." | 5.19 | Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( Anurathapan, U; Choeyprasert, W; Chuansumrit, A; Hongeng, S; Nartthanarung, A; Pakakasama, S; Sirachainan, N; Songdej, D, 2014) |
| "The EICESS-92 Trial compared the efficacy of cyclophosphamide and ifosfamide in patients with Ewing sarcoma." | 5.14 | Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma. ( DuBois, SG; Grier, HE, 2009) |
| "The aim of this study was to evaluate the maximum tolerated dose (MTD) and safety of the combination of non- pegylated liposomal doxorubicin (Myocet) and ifosfamide in patients with metastatic soft tissue sarcomas." | 5.14 | Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas. ( Barbato, A; Bertuzzi, A; Di Comite, G; Lutman, RF; Mussi, C; Santoro, A; Stroppa, E, 2010) |
| "Dynamic PET studies with (18)F-FDG were performed in patients with metastatic soft tissue sarcomas who received conventional chemotherapy with doxorubicin hydrochloride (Adriamycin) and ifosfamide (AI-G)." | 5.14 | Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis. ( Dimitrakopoulou-Strauss, A; Egerer, G; Haberkorn, U; Kasper, B; Schmitt, T; Strauss, LG; Vasamiliette, J, 2010) |
| "High-dose ifosfamide plus doxorubicin is an active regimen for all subtypes of gynecological sarcomas." | 5.12 | Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. ( Cerny, T; Dietrich, D; Fey, M; Honegger, HP; Jundt, G; Leyvraz, S; Lissoni, A; Sessa, C; Zweifel, M, 2006) |
| "This phase I study evaluated the toxicity of first-line combined pegylated liposomal doxorubicin (Caelyx) and ifosfamide in patients with advanced and/or metastatic soft tissue sarcomas." | 5.12 | Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas. ( Blay, J; Christensen, TB; Daugaard, S; Hermans, C; Judson, I; Marreaud, S; Nielsen, OS; Pink, D; Reichardt, P; van Glabbeke, M, 2006) |
| "The established clinical activity of docetaxel and ifosfamide as single agents in anthracycline pre-treated breast cancer, led us to conduct a phase I-II study to define the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and clinical activity of the docetaxel+ifosfamide combination in this setting." | 5.12 | Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study. ( Gassiamis, A; Karabelis, A; Kosmas, C; Malamos, N; Mylonakis, N; Polyzos, A; Skopelitis, H; Tsakonas, G; Tsavaris, N, 2007) |
| "Adding ifosfamide and etoposide to standard therapy does not improve outcomes of patients with Ewing's sarcoma or PNET of bone with metastases at diagnosis." | 5.11 | Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study. ( Dickman, PS; Donaldson, SS; Fryer, CJ; Gebhardt, MC; Grier, HE; Krailo, MD; Link, MP; Meyers, PA; Miser, JS; Moore, S; Perlman, EJ; Pritchard, DJ; Rausen, AR; Tarbell, NJ; Vietti, TJ, 2004) |
| "To study the role of single agent carboplatin chemotherapy in patients with metastatic seminoma based on the data from two randomised trials." | 5.11 | Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials. ( Bokemeyer, C; Clemm, C; Gerl, A; Hartmann, JT; Horwich, A; Kanz, L; Kollmannsberger, C; Meisner, C; Oliver, T; Rückerl, CP; Schmoll, HJ; Stenning, S, 2004) |
| "The objectives of this trial were to estimate the response rate, progression-free survival, and overall survival of patients who received therapy with etoposide and high-dose ifosfamide, and to define the toxicity of this combination when provided with standard chemotherapy in patients with newly diagnosed metastatic osteosarcoma." | 5.10 | Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. ( Bernstein, M; Devidas, M; Ferguson, W; Gebhardt, MC; Goorin, AM; Grier, HE; Harris, MB; Link, M; Schwartz, CL; Siegal, GP, 2002) |
| "A prospective trial to evaluate the efficacy and toxicity of ifosfamide (IFX) and vinorelbine (VNB) in patients with prior anthracycline therapy for metastatic breast cancer (MBC) was conducted." | 5.09 | Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy. ( Aziz, Z; Qazi, S; Rehman, A, 1999) |
| "Forty-six patients were included in a phase II study to evaluate the response rate and toxicity of a combination of ifosfamide and vinorelbine in metastatic breast cancer patients previously treated with one or more regimens of chemotherapy." | 5.09 | Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy. ( Albistur, JJ; Barnadas, A; Constenla, M; Estévez, LG; Frau, A; Lizón, J; Lobo, F; Martínez, P; Méndez, M; Provencio, M; Sánchez, MJ, 1999) |
| "Twenty-four children and adolescents with metastatic sarcomas received VACIME chemotherapy, consisting of eight courses of vincristine 2 mg/m(2) on day 0; doxorubicin 20 mg/m(2)/day on days 0-3; cyclophosphamide 360 mg/m(2)/day on days 0-4; ifosfamide 1,800 mg/m(2)/day on days 0-4; mesna 2,400 mg/m(2)/day; and etoposide 100 mg/m(2)/day on days 0-4." | 5.09 | Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas. ( Conrad, EU; Felgenhauer, J; Hawkins, D; Lindsley, K; Miser, JS; Pendergrass, T, 2000) |
| "Patients with locally advanced or metastatic soft tissue sarcoma refractory to treatment with anthracyclines and ifosfamide were enrolled into the present phase II study." | 5.09 | Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. ( Amann, G; Attems, Y; Brodowicz, T; Fiebiger, WC; Hejna, M; Köstler, WJ; Krainer, M; Tomek, S; Wiltschke, CH; Zielinski, CC, 2001) |
| " ifosfamide and etoposide) and to improve overall survival of previously untreated patients with metastatic rhabdomyosarcoma." | 5.09 | Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group. ( Breitfeld, PP; Crist, WM; Donaldson, SS; Lobe, T; Lyden, E; Maurer, HM; Raney, RB; Ruymann, FB; Teot, LA; Wharam, M, 2001) |
| "Twenty patients with locally advanced or metastatic breast cancer were treated with four cycles of ifosfamide/mesna 5 g m-2 and epirubicin 60 mg m-2 every 14 days with granulocyte colony-stimulating factor (G-CSF, Filgrastim)." | 5.08 | The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer. ( Calvert, AH; Cantwell, BM; Chapman, F; Gumbrell, L; Lind, MJ; McCann, E; Middleton, I; Millward, MJ; Proctor, M; Simmonds, D, 1995) |
| "We conducted a phase I/II trial to investigate the activity of ifosfamide/carboplatin/etoposide given over 2 or 3 days (mini-ICE) to patients with anthracycline-refractory or recurrent metastatic breast cancer." | 5.08 | Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships. ( Elfenbein, GJ; Fields, KK; Perkins, JB, 1995) |
| "This study was designed to test if the activity of a phase II agent, ifosfamide, would have been underestimated if it was tested exclusively in a population of children and young adults with recurrent osteosarcoma." | 5.08 | Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study. ( Ayala, AG; Cantor, AB; Ferguson, WS; Goorin, AM; Harris, MB; Holbrook, T; Link, MP; Shochat, SJ, 1995) |
| "Ifosfamide is an oxazaphosphorine analogue of cyclophosphamide with proven activity in breast cancer but substantial urotoxicity." | 5.08 | Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer. ( Hartmann, LC; Ingle, JN; Krook, JE; Mailliard, JA; Wieand, HS, 1995) |
| "To determine the effectiveness and toxicity of ifosfamide chemotherapy in women with metastatic or recurrent endometrial stromal sarcomas unexposed to other chemotherapy." | 5.08 | Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group. ( Blessing, JA; DiSaia, PJ; Park, R; Rosenshein, N; Sutton, G, 1996) |
| "In a randomized, phase II trial, we evaluated the effectiveness of continued chemotherapy with epirubicin/ ifosfamide versus unmaintained treatment interruption in advanced metastatic breast cancer." | 5.08 | Epirubicin and ifosfamide in metastatic breast cancer. ( Bartels, H; Becher, R; DeDycker, R; Fischedick, AR; Halabi, S; Hartwich, G; Hawig, I; Hayungs, J; Hering, KG; Hirche, H; Höfeler, H; Huhn, R; Illiger, HJ; Kloke, O; Ohl, S; Pielken, HJ; Rieche, K; Seeber, S; Szanto, J; Wolf, E, 1996) |
| "To evaluate the efficacy and toxicity of the combination of ifosfamide (IFX) and vinorelbine (VNB) as first-line chemotherapy in metastatic breast cancer (MBC)." | 5.08 | Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer. ( Acuña, JM; Acuña, LA; Amato, S; Barbieri, MR; Cuevas, MA; Dominguez, ME; Lacava, JA; Langhi, MJ; Leone, BA; Machiavelli, MR; Ortiz, EH; Perez, JE; Rodriguez, R; Romero, AO; Sabatini, CL; Salvadori, MA; Vallejo, CT, 1996) |
| "The new combination of ifosfamide and vinorelbine was evaluated in a phase II study of patients with metastatic breast cancer." | 5.08 | Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer. ( Cafiero, F; Gipponi, M; Landucci, M; Pronzato, P; Queirolo, P; Vaira, F; Vigani, A, 1997) |
| "The aim of this paper is to evaluate the activity of ifosfamide in previously treated patients with metastatic breast cancer." | 5.08 | Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. ( Esparza-Guerra, L; Holmes, FA; Hortobagyi, GN; Valero, V; Walters, RS, 1998) |
| " Those with high volume metastases will receive either BEP or etoposide, ifosfamide and cisplatinum (VIP)." | 5.06 | Potential advances in combination chemotherapy for advanced testicular cancer. ( Boven, E; De Pauw, M; Harris, A; Jones, W; Kaye, SB; Sleijfer, D; Splinter, T; Stoter, G; Ten Bokkel Huinink, W; Van Oosterom, A, 1988) |
| "A combination of 5-fluorouracil (5-FU), adriamycin, and cyclophosphamide (FAC) was compared to a combination of 5-FU, adriamycin, and ifosfamide (FAI) in the treatment of metastatic breast cancer." | 5.04 | Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. ( Blumenschein, GR; Bodey, GP; Buzdar, AU; Hersh, EM; Hortobagyi, GN; Legha, SS; Tashima, CK; Yap, HY, 1979) |
| "This meta-analysis examines the role of ifosfamide-based combination chemotherapy in patients with advanced soft tissue sarcoma." | 4.84 | Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. ( Blackstein, M; Haynes, AE; Stys-Norman, D; Verma, S; Younus, J, 2008) |
| "5%) nonmetastatic soft tissue sarcoma received neoadjuvant chemoradiotherapy with ifosfamide (1." | 3.83 | Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience. ( Agaimy, A; Croner, R; Fietkau, R; Hohenberger, W; Lettmaier, S; Ott, O; Semrau, S; Stubbe, F; Vassos, N, 2016) |
| "A retrospective study was performed to assess toxicity and response rate of ifosfamide salvage treatment for dogs diagnosed with metastatic osteosarcoma (OSA)." | 3.80 | Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma. ( Batschinski, K; Dervisis, NG; Kitchell, BE, 2014) |
| "We evaluated the efficacy and tolerability of combined paclitaxel and ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer (MBC)." | 3.76 | Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance. ( Chang, H; Choi, HJ; Chung, HC; Kim, JH; Kim, SI; Kim, YT; Koo, JS; Moon, YW; Park, BW; Park, S; Roh, JK; Sohn, JH, 2010) |
| "The efficacy of zoledronic acid (ZOL), with or without the anticancer drug ifosfamide (IFO), was tested on primary bone tumor growth using a rat-transplantable model of osteosarcoma." | 3.73 | Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. ( Blanchard, F; Charrier, C; Coipeau, P; Couillaud, S; Gouin, F; Heymann, D; Heymann, MF; Ory, B; Redini, F; Thiery, JP, 2005) |
| "Twenty-three children and adolescents with metastatic sarcomas received vincristine, doxorubicin, cyclophosphamide, ifosfamide, sodium mercaptoethanesulfonate (mensa), and etoposide (VACIME) chemotherapy, consisting of 8 courses of vincristine 2 mg/m(2) on Day 0, doxorubicin 37." | 3.71 | Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. ( Douglas, J; Felgenhauer, J; Gooley, T; Hawkins, DS; Kreissman, S; Park, J; Pendergrass, TW; Rowley, SD; Sanders, JE; Thomson, B, 2002) |
| "Ifosfamide is a leading drug in soft tissue sarcoma therapy." | 3.70 | Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. ( Bergnolo, P; Boglione, A; Bumma, C; Colussi, AM; Comandone, A; Dal Canton, O; Frustaci, S; Leone, L; Monteleone, M; Oliva, C, 1998) |
| "25 previously untreated patients with inoperable or metastatic adenocarcinoma of the oesophagus or oesophageal-gastric junction area were treated with ifosfamide 6 g/m2 over 48 hours, combined with mesna 6 g/m2." | 3.68 | Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; Tilanus, HW; van der Gaast, A, 1991) |
| "The combination of ifosfamide (IFO) and epirubicin (EPI) has been found to be an effective regimen in the treatment of metastatic tumours and shows remarkable activity in heavily pretreated breast cancer patients." | 3.68 | Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours. ( Hoffmann, W; Könner, J; Migeod, F; Seeber, S; Weidmann, B, 1990) |
| "Thirty-seven patients with widely metastatic malignant melanoma were treated with one of three chemotherapy regimens, incorporating high-dose dacarbazine (DTIC)." | 3.67 | High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma. ( Carr, T; Chadwick, G; Craig, P; Jones, R; Lind, M; Morgenstern, G; Thatcher, D, 1989) |
| "Ifosfamide was tested in a phase II study in 12 evaluable patients with advanced malignant melanoma." | 3.67 | Phase II study with ifosfamide in advanced malignant melanoma. ( Bajetta, E; Bonfante, V; Ferrari, L; Negretti, E, 1988) |
| "Fifty-three patients with inoperable non-small cell bronchial carcinoma were treated at four-weekly intervals with two cytostatic drugs, doxorubicin (50 mg/m2 on day 1) and ifosfamide (2000 mg/m2 on days 1-3)." | 3.66 | [Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide]. ( Göbel, D; Matthiessen, W; Stempinski, E; Thalmann, U, 1983) |
| "" The regimen included an intensification of ifosfamide dosing from 1,800 mg/m(2) /day × 5 days per cycle to 2,800 mg/m(2) /day × 5 days per cycle." | 2.80 | Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma. ( Chou, AJ; Goodbody, CM; Magnan, H; Pratilas, CA; Riedel, E; Wexler, LH, 2015) |
| " Pharmacokinetic analysis revealed a linear relation between the area under the concentration-versus-time curve (AUC) and dose." | 2.75 | Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors. ( Akashi, Y; Fukuoka, M; Miyazaki, M; Nakagawa, K; Okamoto, I; Ozaki, T; Satoh, T; Shimizu, T; Tamura, K, 2010) |
| "Prognosis of patients with metastatic soft tissue sarcoma remains poor." | 2.75 | Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study. ( Dietrich, S; Egerer, G; Ho, AD; Kasper, B; Scharrenbroich, I; Schmitt, T; Wuchter, P, 2010) |
| "Grade 3/4 neutropenia was observed in 21 % of patients and grade 3/4 febrile neutropenia was seen in only one patient." | 2.73 | Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma. ( Ahn, JS; Ahn, MJ; Hwang, IG; Im, YH; Kang, WK; Lee, SC; Lim, HY; Park, BB; Park, K, 2008) |
| "Twelve patients in stage IIIB cervical cancer were submitted to NAC and 12 (control group)--received standart pelvic radiation to whole pelvis--52 Gy." | 2.71 | [Effect of neoadjuvant chemotherapy in the treatment of patients with stage IIIB cervical cancer]. ( Gorchev, G; Kornovski, Ia, 2003) |
| "Ifosfamide was administered intravenously at the dose of 1,200 mg/m2 from day 1 to day 5 with uroprotection of Mesna in fusion at 0, 3, and 6 hours following initiation of IFO." | 2.70 | [Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma]. ( Guan, ZZ; He, YJ; Huang, HQ; Jiang, WQ; Li, YH; Teng, XY; Zhou, ZM, 2002) |
| "Gemcitabine was administered at a dose of 800 mg/m2 on days 1 and 8 and ifosfamide at a dose of 2 g/m2 on days 1 and 8 with adequate amount of Mesna." | 2.70 | Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. ( Aravantinos, G; Bafaloukos, D; Dimopoulos, MA; Kalofonos, H; Kiamouris, C; Nicolaides, C; Pectasides, D; Visvikis, A; Xiros, N, 2001) |
| "Two hundred one patients had no metastases." | 2.69 | Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. ( Cotterill, S; Craft, A; Grimer, R; Imeson, J; Lewis, I; Malcolm, A; Souhami, R; Spooner, D, 1998) |
| " Ifosfamide with G-CSF in combination with doxorubicin or paclitaxel achieves effective mobilization of PBPC and anti-tumor activity with minimal toxicity." | 2.69 | Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer. ( Brettell, M; Briggs, P; Chapple, P; Francis, P; Gardyn, J; Gates, P; Januszewicz, EH; Juneja, S; Millward, MJ; Prince, HM; Quinn, M; Richardson, G; Rischin, D; Scarlett, J; Toner, GC; Wolf, M, 1999) |
| "Twenty-five patients with metastatic breast cancer were treated with ICE after failure of previous chemotherapy." | 2.69 | Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer. ( Asbury, R; Boros, L; Chang, AY; Garrow, G; Hui, L; Rubins, J, 1999) |
| "Consolidation of remissions of pPNET metastatic to bone and bone marrow remains a therapeutic challenge." | 2.68 | Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. ( Aledo, A; Boland, P; Casper, ES; Gerald, WL; Healey, JH; Heller, G; Kushner, BH; La Quaglia, MP; Meyers, PA; Wollner, N, 1995) |
| "Of 21 patients with testicular tumors who could be evaluated, 10 (47%) achieved a CR." | 2.68 | High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. ( André, T; Bonnak, H; Bouleuc, C; Donsimoni, R; Esteso, A; Firmin, C; Gerota, J; Izrael, V; Lotz, JP; Merad, Z, 1995) |
| "Patients with metastatic breast cancer refractory to all standard dose therapy were treated with escalating doses of mitoxantrone (45 to 105 mg/m2) and thiotepa (900 to 1,350 mg/m2) followed by autologous stem cell rescue." | 2.67 | Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. ( Ballester, OF; Elfenbein, GJ; Fields, KK; Foody, MC; Hiemenz, JW; Janssen, WE; Kronish, LE; Perkins, JB; Zorsky, PE, 1993) |
| "Localized soft tissue sarcoma may be cured with complete tumor excision, but overall, outcomes are sub-optimal." | 2.58 | Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy. ( Charlson, J, 2018) |
| "Proximal epithelioid sarcoma (PES) originating from the pleura is a clinical entity rarely reported in the literature." | 2.53 | [Pleural epithelioid sarcoma: about a case and review of the literature]. ( Akasbi, Y; Amara, B; Arifi, S; Chatar, A; Fatemi, H; Lemrabet, FZ; Mellas, N; Ouahbi, H; Oualla, K; Tizniti, S, 2016) |
| "Osteosarcoma is a rare tumor and any effort should be made to improve the level of International collaboration." | 2.52 | An update on chemotherapy for osteosarcoma. ( Ferrari, S; Serra, M, 2015) |
| "Concerning penis cancer, the optimal protocols validated by a high level of evidence are missing." | 2.49 | [Chemotherapy in male external genital organs (testicular and penile cancer)]. ( Bastide, C; Bruyère, F; Deville, JL; Flechon, A; Guy, L; Karsenty, G, 2013) |
| "Cervical cancer is one of the most common cancers in women." | 2.42 | [The guidelines for diagnostics and treatment of cervical cancer]. ( Inciūra, A; Juozaityte, E, 2004) |
| "Doxorubicin, the most active agent for breast cancer, was studied first." | 2.39 | Paclitaxel combination therapy in the treatment of metastatic breast cancer. ( Holmes, FA, 1996) |
| "Metastases from cystosarcoma phyllodes are rare, and treatment generally is ineffective." | 2.38 | Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes. ( Fisher, C; Hawkins, RE; McKinna, JA; Schofield, JB; Wiltshaw, E, 1992) |
| "Prognosis of metastatic malignant peripheral nerve sheath tumor (MPNST) is poor and the role of chemotherapy is controversial." | 1.56 | Metastatic Malignant Peripheral Nerve Sheath Tumor With NF1 Successfully Treated With 'Gradual Subtraction' ICE Chemotherapy. ( Kakuda, Y; Katagiri, H; Miyagi, M; Murata, H; Takahashi, M; Wang, Y; Wasa, J, 2020) |
| "Soft tissue sarcomas are a group of tumors derived from the mesenchymal origin." | 1.56 | Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion. ( Al-Rohil, RN; Bentley, RC; Cardona, DM; Feng, X; Jour, G; Shen, G; Underwood, CIM, 2020) |
| "On multivariate analysis, metastasectomy and objective response or stable disease achieved with first-line chemotherapy were indicators for better overall survival." | 1.51 | Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center. ( Cornillie, J; Debiec-Rychter, M; Hompes, D; Langmans, C; Schöffski, P; Sciot, R; van Cann, T; Vandenbempt, I; Wozniak, A, 2019) |
| "Ameloblastoma is generally characterized as a benign tumor originating in odontogenic epithelium." | 1.51 | MAID chemotherapy regimen as a treatment strategy for metastatic malignant ameloblastoma: A case report. ( Li, D; Liu, Y; Qiao, L; Sun, M; Wang, L; Xu, S, 2019) |
| "Multivariate analysis identified LN metastases (HR 6." | 1.39 | Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen. ( Abu Sheikha, A; Al Mousa, A; Salah, S; Salem, A; Sultan, I; Yaser, S, 2013) |
| "Patients with infratentorial brain metastases of highly malignant pediatric non-epithelial tumors are in a severe clinical state, but still can have longer and useful lives with aggressive multimodal treatments combined with radical surgical resection." | 1.37 | Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports. ( Kumabe, T; Niizuma, H; Osawa, S; Saito, R; Sonoda, Y; Tominaga, T; Watanabe, M, 2011) |
| " No significant dose-response relationship was found in terms of LRC." | 1.37 | Sequential or concomitant chemotherapy in limited stage small-cell lung cancer. ( Anchisi, S; Bieri, S; Elhfidh, M; Khanfir, K; Matzinger, O; Mirimanoff, RO; Ozsahin, M; Zouhair, A, 2011) |
| "Ifosfamide is an alkylating agent with well-demonstrated efficacy against STS, and dose-dependent activity." | 1.37 | High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients. ( Baek, KK; Chang, MH; Han, B; Lee, J; Lee, SH; Lim, T; Park, JO, 2011) |
| "Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high rate of locoregional and distant failure." | 1.35 | Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer. ( Akrivos, T; Daladimos, T; Kalinoglou, N; Karabelis, A; Karvounis, N; Kosmas, C; Malamos, N; Mylonakis, N; Tsakonas, G; Tsavaris, N; Vorgias, G, 2009) |
| "A 30-year-old man was diagnosed with testicular cancer, and underwent a radical orchiectomy." | 1.35 | [A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin]. ( Egawa, S; Hatano, T; Ito, H; Kishimoto, K; Tomita, M; Wada, T; Yanada, S, 2008) |
| "Fungal, viral, and nosocomial infections were uncommon." | 1.35 | Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors. ( Bosl, GJ; Feldman, DR; Ishill, N; Jathavedam, A; Motzer, RJ; Patil, S; Turkula, S; Weinstock, DM, 2008) |
| "Alveolar soft part sarcoma is a rare malignant tumor with unusual clinical behavior." | 1.33 | Alveolar soft part sarcoma: a rare and enigmatic entity. ( Anderson, ME; Gebhardt, MC; Hornicek, FJ; Mankin, HJ; Raskin, KA, 2005) |
| "Synovial sarcoma is an extremely rare primary pulmonary tumor whose description is based on a limited number of cases." | 1.32 | [Primary pulmonary synovial sarcoma: a report and diagnosis of 2 cases]. ( Baldo Padró, X; Bernadó Turmo, L; Haro Estarriol, M; Rubio Goday, M; Sebastián Quetglas, F; Viñas Villaró, G, 2003) |
| "The number of metastases at diagnosis and the completeness of surgical resection of all clinically detected tumor sites are of independent prognostic value in patients with proven primary metastatic osteosarcoma." | 1.32 | Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. ( Bielack, SS; Branscheid, D; Flege, S; Gadner, H; Jundt, G; Jürgens, H; Kabisch, H; Kager, L; Kastner, U; Kempf-Bielack, B; Kotz, R; Pötschger, U; Reichardt, P; Salzer-Kuntschik, M; Winkelmann, W; Zoubek, A, 2003) |
| "Thirty-seven patients had distant metastases at presentation." | 1.32 | Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group. ( Hatano, H; Hotta, T; Kawashima, H; Morita, T; Ogose, A; Ueda, T; Yazawa, Y, 2003) |
| " The bioavailability is nearly 100% after oral application, and the main metabolites are 4-hydroxytrofosfamide, and 4-hydroxyifosfamide." | 1.32 | Hypersensitivity pneumonitis associated with the use of trofosfamide. ( Hartmann, JT; Kanz, L; Kopp, HG, 2004) |
| "Twenty-six patients with breast cancer who had relapsed after previously receiving high-dose chemotherapy and autologous hematopoietic cell support received a second course of high-dose cytoreductive therapy and autologous hematopoietic cell support as salvage therapy." | 1.30 | High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. ( Bearman, S; Cagnoni, P; Jones, R; Nieto, Y; Peters, W; Ross, M; Shpall, E; Vredenburgh, J, 1999) |
| "Patients with metastatic breast cancer will receive 4-5 cycles of induction chemotherapy on one of the ongoing Medicine Branch protocols." | 1.29 | Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. ( Chiang, Y; Cowan, KH; Dunbar, CE; Goldspiel, B; Kohler, D; McDonagh, KT; Nienhuis, AW; O'Shaughnessy, JA; Sorrentino, BP; Wilson, W, 1994) |
| "Twelve patients with localized Ewing's sarcoma were treated between 1980-1990 at the Istanbul School of Medicine, Department of Pediatric Oncology-Hematology, Oncology Research and Treatment Center and Our Children Leukemia Foundation." | 1.28 | Ewing's sarcoma: experience with 12 cases. ( Gedikoğlu, G; Zülfikar, B, 1992) |
| "Cerebral metastases occurred in 20% of all patients and was the apparent sole site of relapse in 11% of the CR patients." | 1.28 | Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy. ( Burt, P; Prendiville, J; Radford, J; Ranson, M; Steward, W; Stout, R; Thatcher, N, 1991) |
| "Between 1982 and 1986, 38 patients with soft tissue sarcomas were treated with a combination of ADM/DTIC (group A), another 45 (group B) received ADM/IFO between 1986 and 1990." | 1.28 | Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide. ( Dietel, M; Hossfeld, DK; Schwarz, R; Weh, HJ; Wingberg, D; Zornig, C; Zügel, M, 1990) |
| "All patients had histologically proven renal cell carcinoma with widespread metastases." | 1.27 | [Chemotherapy of metastatic renal cell carcinoma with cis-diamminedichloroplatinum and other drugs]. ( Akimoto, M; Hara, M; Hasegawa, J; Hirasawa, S; Kanamori, S; Kawamura, N; Nishimura, T; Ohhara, M; Okumura, S; Yoshida, K, 1984) |
| "Ifosfamide (Z 4942) is an alkylating agent with the structure of a cyclophosphamide analog." | 1.27 | [Treatment of pain caused by metastases of reactivated prostatic cancer with ifosfamide]. ( Kawai, T; Kihara, K; Sakuramoto, T; Satomi, Y; Takeda, T, 1983) |
| " Analysis of the results according to sex, age, dosage of ifosfamide and degree of histological differentiation of the tumour cells failed to show any influence of these factors on the therapeutic results." | 1.27 | Treatment of advanced malignancies with ifosfamide under protection with mesna. ( Brock, N; Guan, ZZ; He, YJ; Li, GC; Li, JQ, 1988) |
| "Ifosfamide (Holoxan) has an effect as a single drug on testicular carcinoma and shows synergism with cisplatinum in mice." | 1.26 | The value of ifosfamide in the polychemotherapy of metastasized testicular cancer pretreated with chemotherapy. ( Clemm, C; Hartenstein, R; Wilmanns, W, 1982) |
| "153 patients with inoperable malignant tumors were treated by the so-called synchronization therapy with vincristine and ifosfamide." | 1.26 | [Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)]. ( Hartwich, G; Lutz, H; Neidhardt, B, 1978) |
| "12 patients with extensive metastases of malignant testicular tumors and 5 other patients with other rapidly growing metastasizing tumors were treated." | 1.25 | [Cytostatic therapy of tumors under conditions of partial synchronisation with particular reference to malignant tumors of the testicle (author's transl)]. ( Jonas, U; Körner, F; Lund, S, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 21 (11.93) | 18.7374 |
| 1990's | 51 (28.98) | 18.2507 |
| 2000's | 59 (33.52) | 29.6817 |
| 2010's | 42 (23.86) | 24.3611 |
| 2020's | 3 (1.70) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, Y | 1 |
| Katagiri, H | 1 |
| Murata, H | 1 |
| Wasa, J | 1 |
| Miyagi, M | 1 |
| Kakuda, Y | 1 |
| Takahashi, M | 1 |
| Underwood, CIM | 1 |
| Cardona, DM | 1 |
| Bentley, RC | 1 |
| Shen, G | 1 |
| Feng, X | 1 |
| Jour, G | 1 |
| Al-Rohil, RN | 1 |
| Chen, L | 1 |
| Chen, Q | 1 |
| Wu, Y | 1 |
| Zhu, M | 1 |
| Hu, J | 1 |
| Zhuang, Z | 1 |
| Chi, EA | 1 |
| Schweizer, MT | 1 |
| Wang, SY | 1 |
| Xie, L | 1 |
| Liu, ET | 1 |
| Liao, JQ | 1 |
| Chen, G | 1 |
| Wang, SX | 1 |
| Charlson, J | 1 |
| Langmans, C | 1 |
| Cornillie, J | 1 |
| van Cann, T | 1 |
| Wozniak, A | 1 |
| Hompes, D | 1 |
| Sciot, R | 1 |
| Debiec-Rychter, M | 1 |
| Vandenbempt, I | 1 |
| Schöffski, P | 1 |
| Li, D | 1 |
| Xu, S | 1 |
| Sun, M | 1 |
| Qiao, L | 1 |
| Wang, L | 1 |
| Liu, Y | 1 |
| Salah, S | 1 |
| Yaser, S | 1 |
| Salem, A | 1 |
| Al Mousa, A | 1 |
| Abu Sheikha, A | 1 |
| Sultan, I | 1 |
| Ozdemir, O | 1 |
| Ozdemir, P | 1 |
| Veral, A | 1 |
| Uluer, H | 1 |
| Ozhan, MH | 1 |
| Deville, JL | 1 |
| Flechon, A | 2 |
| Bruyère, F | 1 |
| Karsenty, G | 1 |
| Guy, L | 1 |
| Bastide, C | 1 |
| Boye, K | 1 |
| Del Prever, AB | 1 |
| Eriksson, M | 2 |
| Saeter, G | 1 |
| Tienghi, A | 2 |
| Lindholm, P | 2 |
| Fagioli, F | 2 |
| Skjeldal, S | 1 |
| Ferrari, S | 5 |
| Hall, KS | 2 |
| Okuno, S | 1 |
| Petersen, I | 1 |
| Shives, T | 1 |
| Mahoney, M | 1 |
| Haddock, M | 1 |
| Sim, F | 1 |
| O'Connor, MI | 1 |
| Markovic, SN | 1 |
| Maples, W | 1 |
| Kurobe, M | 1 |
| Kawai, K | 1 |
| Oikawa, T | 1 |
| Ichioka, D | 1 |
| Kandori, S | 1 |
| Takaoka, E | 1 |
| Kojima, T | 1 |
| Joraku, A | 1 |
| Suetomi, T | 1 |
| Miyazaki, J | 1 |
| Nishiyama, H | 1 |
| Kakutani, S | 1 |
| Fukuhara, H | 1 |
| Taguchi, S | 1 |
| Nagata, M | 1 |
| Niimi, A | 1 |
| Hattori, M | 1 |
| Miyazaki, H | 2 |
| Fujimura, T | 1 |
| Nakagawa, T | 1 |
| Kume, H | 1 |
| Igawa, Y | 1 |
| Homma, Y | 1 |
| Fizazi, K | 1 |
| Pagliaro, L | 2 |
| Laplanche, A | 1 |
| Mardiak, J | 1 |
| Geoffrois, L | 1 |
| Kerbrat, P | 1 |
| Chevreau, C | 2 |
| Delva, R | 1 |
| Rolland, F | 2 |
| Theodore, C | 1 |
| Roubaud, G | 1 |
| Gravis, G | 1 |
| Eymard, JC | 1 |
| Malhaire, JP | 1 |
| Linassier, C | 1 |
| Habibian, M | 1 |
| Martin, AL | 1 |
| Journeau, F | 1 |
| Reckova, M | 1 |
| Logothetis, C | 1 |
| Culine, S | 1 |
| Choeyprasert, W | 1 |
| Pakakasama, S | 1 |
| Sirachainan, N | 1 |
| Songdej, D | 1 |
| Chuansumrit, A | 1 |
| Anurathapan, U | 1 |
| Hongeng, S | 1 |
| Nartthanarung, A | 1 |
| Hadoux, J | 1 |
| Rey, A | 2 |
| Duvillard, P | 1 |
| Lhommé, C | 1 |
| Balleyguier, C | 1 |
| Haie-Meder, C | 1 |
| Morice, P | 1 |
| Tazi, Y | 1 |
| Leary, A | 1 |
| Larue, C | 1 |
| Pautier, P | 1 |
| Magnan, H | 1 |
| Goodbody, CM | 1 |
| Riedel, E | 1 |
| Pratilas, CA | 1 |
| Wexler, LH | 1 |
| Chou, AJ | 1 |
| Saste, A | 1 |
| Cabrera Fernandez, DF | 1 |
| Gulati, R | 1 |
| Gamalski, S | 1 |
| Nieto, Y | 2 |
| Tu, SM | 1 |
| Bassett, R | 1 |
| Jones, RB | 1 |
| Gulbis, AM | 1 |
| Tannir, N | 1 |
| Kingham, A | 1 |
| Ledesma, C | 1 |
| Margolin, K | 1 |
| Holmberg, L | 1 |
| Champlin, R | 1 |
| Noujaim, J | 1 |
| Thway, K | 1 |
| Jones, RL | 1 |
| Miah, A | 1 |
| Khabra, K | 1 |
| Langer, R | 1 |
| Kasper, B | 3 |
| Judson, I | 2 |
| Benson, C | 1 |
| Kollàr, A | 1 |
| Serra, M | 2 |
| Stubbe, F | 1 |
| Agaimy, A | 1 |
| Ott, O | 1 |
| Lettmaier, S | 1 |
| Vassos, N | 1 |
| Croner, R | 1 |
| Hohenberger, W | 1 |
| Fietkau, R | 1 |
| Semrau, S | 1 |
| O'Kane, G | 1 |
| Bracken-Clarke, D | 1 |
| Gardiner, N | 1 |
| Lee, G | 1 |
| Ni Chonghaile, M | 1 |
| Power, D | 1 |
| Daly, PA | 1 |
| McCaffrey, J | 1 |
| Bacon, CL | 1 |
| Conneally, E | 1 |
| Flynn, C | 1 |
| Vandenberghe, E | 1 |
| Kennedy, MJ | 1 |
| Browne, PV | 1 |
| O'Donnell, DM | 1 |
| Hayden, PJ | 1 |
| Seddon, B | 1 |
| Hattinger, CM | 1 |
| Biason, P | 1 |
| Iacoboni, E | 1 |
| Gagno, S | 1 |
| Fanelli, M | 1 |
| Tavanti, E | 1 |
| Vella, S | 1 |
| Roli, A | 1 |
| Roncato, R | 1 |
| Giodini, L | 1 |
| Scotlandi, K | 1 |
| Picci, P | 2 |
| Toffoli, G | 1 |
| Ouahbi, H | 1 |
| Akasbi, Y | 1 |
| Oualla, K | 1 |
| Amara, B | 1 |
| Chatar, A | 1 |
| Tizniti, S | 1 |
| Fatemi, H | 1 |
| Lemrabet, FZ | 1 |
| Arifi, S | 1 |
| Mellas, N | 1 |
| Gilman, AL | 1 |
| Oesterheld, J | 1 |
| Kollmannsberger, C | 3 |
| Bokemeyer, C | 5 |
| Fayette, J | 1 |
| Penel, N | 1 |
| Blay, JY | 1 |
| Cupissol, D | 1 |
| Thyss, A | 1 |
| Guillemet, C | 1 |
| Rios, M | 1 |
| Fargeot, P | 1 |
| Bay, JO | 1 |
| Mathoulin-Pelissier, S | 1 |
| Coindre, JM | 1 |
| Bui-Nguyen, B | 1 |
| DuBois, SG | 1 |
| Grier, HE | 3 |
| Mountzios, G | 1 |
| Dimopoulos, MA | 4 |
| Bamias, A | 1 |
| Vourli, G | 1 |
| Kalofonos, H | 2 |
| Aravantinos, G | 3 |
| Fountzilas, G | 1 |
| Papadimitriou, CA | 2 |
| Shimizu, T | 1 |
| Okamoto, I | 1 |
| Tamura, K | 1 |
| Satoh, T | 1 |
| Miyazaki, M | 1 |
| Akashi, Y | 1 |
| Ozaki, T | 1 |
| Fukuoka, M | 1 |
| Nakagawa, K | 1 |
| Briccoli, A | 2 |
| Rocca, M | 2 |
| Salone, M | 1 |
| Palmerini, E | 1 |
| Balladelli, A | 1 |
| Ferrari, C | 1 |
| Di Fiore, M | 1 |
| Bacci, G | 2 |
| Stroppa, E | 1 |
| Bertuzzi, A | 1 |
| Di Comite, G | 1 |
| Mussi, C | 1 |
| Lutman, RF | 1 |
| Barbato, A | 1 |
| Santoro, A | 1 |
| Kosmas, C | 3 |
| Mylonakis, N | 2 |
| Tsakonas, G | 2 |
| Vorgias, G | 1 |
| Karvounis, N | 1 |
| Tsavaris, N | 2 |
| Daladimos, T | 1 |
| Kalinoglou, N | 1 |
| Malamos, N | 2 |
| Akrivos, T | 1 |
| Karabelis, A | 2 |
| Scharrenbroich, I | 1 |
| Schmitt, T | 2 |
| Wuchter, P | 1 |
| Dietrich, S | 1 |
| Ho, AD | 1 |
| Egerer, G | 2 |
| Moon, YW | 1 |
| Sohn, JH | 1 |
| Choi, HJ | 1 |
| Chang, H | 1 |
| Park, BW | 1 |
| Kim, SI | 1 |
| Park, S | 1 |
| Koo, JS | 1 |
| Kim, YT | 1 |
| Roh, JK | 1 |
| Chung, HC | 1 |
| Kim, JH | 1 |
| Dimitrakopoulou-Strauss, A | 1 |
| Strauss, LG | 1 |
| Vasamiliette, J | 1 |
| Haberkorn, U | 1 |
| Staudacher, L | 1 |
| Cottu, PH | 1 |
| Diéras, V | 1 |
| Vincent-Salomon, A | 1 |
| Guilhaume, MN | 1 |
| Escalup, L | 1 |
| Dorval, T | 1 |
| Beuzeboc, P | 1 |
| Mignot, L | 1 |
| Pierga, JY | 1 |
| Daugaard, G | 1 |
| Skoneczna, I | 1 |
| Aass, N | 1 |
| De Wit, R | 1 |
| De Santis, M | 1 |
| Dumez, H | 1 |
| Marreaud, S | 2 |
| Collette, L | 1 |
| Lluch, JRG | 1 |
| Schmoll, HJ | 4 |
| Osawa, S | 1 |
| Kumabe, T | 1 |
| Saito, R | 1 |
| Sonoda, Y | 1 |
| Niizuma, H | 1 |
| Watanabe, M | 1 |
| Tominaga, T | 1 |
| Mora, J | 1 |
| de Torres, C | 1 |
| Parareda, A | 1 |
| Torner, F | 1 |
| Galván, P | 1 |
| Rodríguez, E | 1 |
| Cardesa, T | 1 |
| Salvador, H | 1 |
| Suñol, M | 1 |
| Huguet, R | 1 |
| Cruz, O | 1 |
| Collins, IM | 1 |
| Thomas, DM | 1 |
| Khanfir, K | 1 |
| Elhfidh, M | 1 |
| Anchisi, S | 1 |
| Matzinger, O | 1 |
| Bieri, S | 1 |
| Mirimanoff, RO | 1 |
| Ozsahin, M | 1 |
| Zouhair, A | 1 |
| Lee, SH | 1 |
| Chang, MH | 1 |
| Baek, KK | 1 |
| Han, B | 1 |
| Lim, T | 1 |
| Lee, J | 1 |
| Park, JO | 1 |
| Ray-Coquard, I | 1 |
| Luksch, R | 1 |
| Barbieri, E | 1 |
| Gandola, L | 1 |
| Ruggieri, P | 1 |
| Daolio, P | 1 |
| Prete, A | 1 |
| Bisogno, G | 2 |
| Tamburini, A | 1 |
| Grignani, G | 1 |
| Abate, ME | 1 |
| Podda, M | 1 |
| Smeland, S | 1 |
| Hervonen, P | 1 |
| Tulijoki, T | 1 |
| Kellokumpu-Lehtinen, P | 1 |
| Frøen, H | 1 |
| Brennhovd, B | 1 |
| Abeler, VM | 1 |
| Madsbu, UE | 1 |
| Lehne, G | 1 |
| Batschinski, K | 1 |
| Dervisis, NG | 1 |
| Kitchell, BE | 1 |
| Hawkins, DS | 1 |
| Felgenhauer, J | 2 |
| Park, J | 1 |
| Kreissman, S | 1 |
| Thomson, B | 1 |
| Douglas, J | 1 |
| Rowley, SD | 1 |
| Gooley, T | 1 |
| Sanders, JE | 1 |
| Pendergrass, TW | 1 |
| Rozan, O | 1 |
| Janot, F | 1 |
| Oberlin, O | 2 |
| Schwaab, G | 1 |
| Quintana, E | 2 |
| Tran Ba Huy, P | 1 |
| Georges, B | 1 |
| Luboinski, B | 1 |
| Huang, HQ | 1 |
| Zhou, ZM | 1 |
| Li, YH | 1 |
| Jiang, WQ | 1 |
| He, YJ | 2 |
| Teng, XY | 1 |
| Guan, ZZ | 2 |
| Souquet, PJ | 1 |
| Tan, EH | 1 |
| Rodrigues Pereira, J | 1 |
| Van Klaveren, R | 1 |
| Price, A | 1 |
| Gatzemeier, U | 1 |
| Jaworski, M | 1 |
| Burillon, JP | 1 |
| Aubert, D | 1 |
| Janinis, J | 1 |
| McTiernan, A | 1 |
| Driver, D | 1 |
| Mitchell, C | 1 |
| Cassoni, AM | 1 |
| Pringle, J | 1 |
| Kilby, A | 1 |
| Whelan, JS | 1 |
| Indrová, M | 1 |
| Bubeník, J | 1 |
| Mikysková, R | 1 |
| Mendoza, L | 1 |
| Símová, J | 1 |
| Bieblová, J | 1 |
| Jandlová, T | 1 |
| Jinoch, P | 1 |
| Smahel, M | 1 |
| Vonka, V | 1 |
| Pajtasz-Piasecka, E | 1 |
| Haro Estarriol, M | 1 |
| Baldo Padró, X | 1 |
| Rubio Goday, M | 1 |
| Sebastián Quetglas, F | 1 |
| Viñas Villaró, G | 1 |
| Bernadó Turmo, L | 1 |
| Kager, L | 1 |
| Zoubek, A | 1 |
| Pötschger, U | 1 |
| Kastner, U | 1 |
| Flege, S | 1 |
| Kempf-Bielack, B | 1 |
| Branscheid, D | 1 |
| Kotz, R | 1 |
| Salzer-Kuntschik, M | 1 |
| Winkelmann, W | 1 |
| Jundt, G | 2 |
| Kabisch, H | 1 |
| Reichardt, P | 2 |
| Jürgens, H | 1 |
| Gadner, H | 1 |
| Bielack, SS | 1 |
| Ogose, A | 1 |
| Yazawa, Y | 1 |
| Ueda, T | 1 |
| Hotta, T | 1 |
| Kawashima, H | 1 |
| Hatano, H | 1 |
| Morita, T | 1 |
| Donati, D | 1 |
| Longhi, A | 1 |
| Bertoni, F | 1 |
| Bacchini, P | 1 |
| Giacomini, S | 1 |
| Forni, C | 1 |
| Manfrini, M | 1 |
| Galletti, S | 1 |
| Vrdoljak, E | 1 |
| Hamm, W | 1 |
| Omrcen, T | 1 |
| Prskalo, T | 1 |
| Gorchev, G | 1 |
| Kornovski, Ia | 1 |
| Inciūra, A | 1 |
| Juozaityte, E | 1 |
| Kopp, HG | 1 |
| Kanz, L | 4 |
| Hartmann, JT | 3 |
| Miser, JS | 2 |
| Krailo, MD | 1 |
| Tarbell, NJ | 1 |
| Link, MP | 2 |
| Fryer, CJ | 1 |
| Pritchard, DJ | 1 |
| Gebhardt, MC | 3 |
| Dickman, PS | 1 |
| Perlman, EJ | 1 |
| Meyers, PA | 2 |
| Donaldson, SS | 2 |
| Moore, S | 1 |
| Rausen, AR | 1 |
| Vietti, TJ | 1 |
| Stenning, S | 1 |
| Horwich, A | 1 |
| Clemm, C | 3 |
| Gerl, A | 1 |
| Meisner, C | 2 |
| Rückerl, CP | 1 |
| Oliver, T | 1 |
| Altundag, K | 1 |
| Aksoy, S | 1 |
| Gullu, I | 1 |
| Altundag, O | 1 |
| Ozyar, E | 1 |
| Yalcin, S | 1 |
| Cengiz, M | 1 |
| Akyol, F | 1 |
| Heymann, D | 1 |
| Ory, B | 1 |
| Blanchard, F | 1 |
| Heymann, MF | 1 |
| Coipeau, P | 1 |
| Charrier, C | 1 |
| Couillaud, S | 1 |
| Thiery, JP | 1 |
| Gouin, F | 1 |
| Redini, F | 1 |
| Orbach, D | 1 |
| Sanchez de Toledo, J | 1 |
| Terrier-Lacombe, MJ | 1 |
| van Unnik, A | 1 |
| Stevens, MC | 1 |
| Anderson, ME | 1 |
| Hornicek, FJ | 1 |
| Raskin, KA | 1 |
| Mankin, HJ | 1 |
| Leyvraz, S | 2 |
| Zweifel, M | 1 |
| Lissoni, A | 1 |
| Cerny, T | 1 |
| Sessa, C | 1 |
| Fey, M | 1 |
| Dietrich, D | 1 |
| Honegger, HP | 1 |
| Indolfi, P | 1 |
| Casale, F | 1 |
| Cecchetto, G | 1 |
| De Salvo, G | 1 |
| Ferrari, A | 1 |
| Donfrancesco, A | 1 |
| Donofrio, V | 1 |
| Martone, A | 1 |
| Di Martino, M | 1 |
| Di Tullio, MT | 1 |
| Nielsen, OS | 1 |
| Christensen, TB | 1 |
| Pink, D | 1 |
| Daugaard, S | 1 |
| Hermans, C | 1 |
| van Glabbeke, M | 1 |
| Blay, J | 1 |
| Cok, G | 1 |
| Göksel, T | 1 |
| Soyer, S | 1 |
| Atil, H | 1 |
| Güzelant, A | 1 |
| Aysan, T | 1 |
| Brain, EG | 1 |
| Rezai, K | 1 |
| Weill, S | 1 |
| Gauzan, MF | 1 |
| Santoni, J | 1 |
| Besse, B | 1 |
| Goupil, A | 1 |
| Turpin, F | 1 |
| Urien, S | 1 |
| Lokiec, F | 1 |
| Kondagunta, GV | 1 |
| Bacik, J | 1 |
| Sheinfeld, J | 1 |
| Bajorin, D | 1 |
| Bains, M | 1 |
| Reich, L | 1 |
| Deluca, J | 1 |
| Budnick, A | 1 |
| Ishill, N | 2 |
| Mazumdar, M | 1 |
| Bosl, GJ | 2 |
| Motzer, RJ | 2 |
| Lin, CC | 1 |
| Hsu, CH | 1 |
| Huang, CY | 1 |
| Keng, HY | 1 |
| Tsai, YC | 1 |
| Huang, KH | 1 |
| Cheng, AL | 1 |
| Pu, YS | 1 |
| Gassiamis, A | 1 |
| Skopelitis, H | 1 |
| Polyzos, A | 1 |
| Piantedosi, FV | 1 |
| Caputo, F | 1 |
| Mazzarella, G | 1 |
| Gilli, M | 1 |
| Pontillo, A | 1 |
| D'Agostino, D | 1 |
| Campbell, S | 1 |
| Marsico, SA | 1 |
| Bianco, A | 1 |
| Goto, T | 1 |
| Okuma, T | 1 |
| Nakada, I | 1 |
| Hozumi, T | 1 |
| Kondo, T | 1 |
| Tascilar, M | 1 |
| Loos, WJ | 1 |
| Seynaeve, C | 1 |
| Verweij, J | 1 |
| Sleijfer, S | 1 |
| Yanada, S | 1 |
| Ito, H | 1 |
| Tomita, M | 1 |
| Wada, T | 1 |
| Hatano, T | 1 |
| Kishimoto, K | 1 |
| Egawa, S | 1 |
| Verma, S | 1 |
| Younus, J | 1 |
| Stys-Norman, D | 1 |
| Haynes, AE | 1 |
| Blackstein, M | 1 |
| Park, BB | 1 |
| Im, YH | 1 |
| Hwang, IG | 1 |
| Lee, SC | 1 |
| Ahn, JS | 1 |
| Ahn, MJ | 1 |
| Lim, HY | 1 |
| Kang, WK | 1 |
| Park, K | 1 |
| Recchia, F | 1 |
| Candeloro, G | 1 |
| Di Staso, M | 1 |
| Necozione, S | 1 |
| Bisegna, R | 1 |
| Bratta, M | 1 |
| Tombolini, V | 1 |
| Rea, S | 1 |
| Jathavedam, A | 1 |
| Feldman, DR | 1 |
| Turkula, S | 1 |
| Patil, S | 1 |
| Weinstock, DM | 1 |
| Okumura, S | 1 |
| Nishimura, T | 1 |
| Yoshida, K | 1 |
| Ohhara, M | 1 |
| Hasegawa, J | 1 |
| Hirasawa, S | 1 |
| Hara, M | 1 |
| Kawamura, N | 1 |
| Kanamori, S | 1 |
| Akimoto, M | 1 |
| Kawai, T | 1 |
| Takeda, T | 1 |
| Kihara, K | 1 |
| Sakuramoto, T | 1 |
| Satomi, Y | 1 |
| Matthiessen, W | 1 |
| Stempinski, E | 1 |
| Göbel, D | 1 |
| Thalmann, U | 1 |
| Hartenstein, R | 1 |
| Wilmanns, W | 1 |
| O'Shaughnessy, JA | 1 |
| Cowan, KH | 1 |
| Nienhuis, AW | 2 |
| McDonagh, KT | 1 |
| Sorrentino, BP | 2 |
| Dunbar, CE | 2 |
| Chiang, Y | 1 |
| Wilson, W | 1 |
| Goldspiel, B | 1 |
| Kohler, D | 1 |
| Lind, MJ | 1 |
| Gumbrell, L | 1 |
| Cantwell, BM | 1 |
| Millward, MJ | 3 |
| Simmonds, D | 1 |
| Proctor, M | 1 |
| Chapman, F | 1 |
| McCann, E | 1 |
| Middleton, I | 1 |
| Calvert, AH | 1 |
| Schleicher, UM | 1 |
| Adam, G | 1 |
| Casser, HR | 1 |
| Füzesi, L | 1 |
| González-Manzano, R | 1 |
| Cid, J | 1 |
| Brugarolas, A | 1 |
| Piasecki, CC | 1 |
| Kushner, BH | 1 |
| Gerald, WL | 1 |
| Healey, JH | 1 |
| La Quaglia, MP | 1 |
| Boland, P | 1 |
| Wollner, N | 1 |
| Casper, ES | 1 |
| Aledo, A | 1 |
| Heller, G | 1 |
| Perkins, JB | 3 |
| Fields, KK | 3 |
| Elfenbein, GJ | 3 |
| Lotz, JP | 1 |
| André, T | 1 |
| Donsimoni, R | 1 |
| Firmin, C | 1 |
| Bouleuc, C | 1 |
| Bonnak, H | 1 |
| Merad, Z | 1 |
| Esteso, A | 1 |
| Gerota, J | 1 |
| Izrael, V | 1 |
| Harris, MB | 2 |
| Cantor, AB | 1 |
| Goorin, AM | 2 |
| Shochat, SJ | 1 |
| Ayala, AG | 1 |
| Ferguson, WS | 1 |
| Holbrook, T | 1 |
| Stewart, FM | 1 |
| Quesenberry, P | 1 |
| O'Shaughnessy, J | 1 |
| Cowan, K | 1 |
| Cottler-Fox, M | 1 |
| Leitman, S | 1 |
| Goodman, S | 1 |
| Harstrick, A | 2 |
| Illiger, HJ | 2 |
| Metzner, B | 2 |
| Räth, U | 1 |
| Hohnloser, J | 1 |
| Berdel, W | 1 |
| Siegert, W | 1 |
| Hiemenz, JW | 1 |
| Janssen, WE | 1 |
| Zorsky, PE | 1 |
| Ballester, OF | 1 |
| Kronish, LE | 1 |
| Foody, MC | 1 |
| Ingle, JN | 1 |
| Krook, JE | 1 |
| Mailliard, JA | 1 |
| Hartmann, LC | 1 |
| Wieand, HS | 1 |
| Moscinski, LC | 1 |
| Droz, JP | 1 |
| Biron, P | 1 |
| Sutton, G | 1 |
| Blessing, JA | 1 |
| Park, R | 1 |
| DiSaia, PJ | 1 |
| Rosenshein, N | 1 |
| Becher, R | 3 |
| Kloke, O | 2 |
| Hayungs, J | 1 |
| Hartwich, G | 2 |
| Bartels, H | 1 |
| Szanto, J | 1 |
| Wolf, E | 1 |
| Halabi, S | 1 |
| Rieche, K | 1 |
| Hering, KG | 1 |
| Ohl, S | 1 |
| DeDycker, R | 1 |
| Huhn, R | 1 |
| Fischedick, AR | 1 |
| Höfeler, H | 2 |
| Pielken, HJ | 1 |
| Hawig, I | 1 |
| Hirche, H | 1 |
| Seeber, S | 2 |
| Leone, BA | 1 |
| Vallejo, CT | 1 |
| Romero, AO | 1 |
| Perez, JE | 1 |
| Cuevas, MA | 1 |
| Lacava, JA | 1 |
| Sabatini, CL | 1 |
| Dominguez, ME | 1 |
| Rodriguez, R | 1 |
| Barbieri, MR | 1 |
| Ortiz, EH | 1 |
| Salvadori, MA | 1 |
| Acuña, LA | 1 |
| Acuña, JM | 1 |
| Langhi, MJ | 1 |
| Amato, S | 1 |
| Machiavelli, MR | 1 |
| Holmes, FA | 2 |
| Fetscher, S | 1 |
| Brugger, W | 1 |
| Engelhardt, R | 1 |
| Hasse, J | 1 |
| Frommhold, H | 1 |
| Wenger, M | 1 |
| Lange, W | 1 |
| Mertelsmann, R | 1 |
| Pronzato, P | 1 |
| Queirolo, P | 1 |
| Landucci, M | 1 |
| Vaira, F | 1 |
| Vigani, A | 1 |
| Gipponi, M | 1 |
| Cafiero, F | 1 |
| Kyriakakis, Z | 1 |
| Kostakopoulos, A | 1 |
| Karayiannis, A | 1 |
| Sofras, F | 1 |
| Zervas, A | 1 |
| Giannopoulos, A | 1 |
| Dimopoulos, C | 1 |
| Colucci, G | 1 |
| Gebbia, V | 1 |
| Galetta, D | 1 |
| Riccardi, F | 1 |
| Cariello, S | 1 |
| Gebbia, N | 1 |
| Shin, DM | 2 |
| Glisson, BS | 2 |
| Khuri, FR | 2 |
| Ginsberg, L | 2 |
| Lawhorn, K | 2 |
| Hong, WK | 2 |
| Lippman, SM | 2 |
| Papadimitrakopoulou, V | 1 |
| Lee, JJ | 1 |
| Gillenwater, AM | 1 |
| Ang, KK | 1 |
| Clayman, GL | 1 |
| Callender, DL | 1 |
| Chen, YM | 1 |
| Liu, JM | 1 |
| Wu, MF | 1 |
| Wu, HW | 1 |
| Lin, WC | 1 |
| Tsai, CM | 1 |
| Perng, RP | 1 |
| Whang-Peng, J | 1 |
| Walters, RS | 1 |
| Valero, V | 1 |
| Esparza-Guerra, L | 1 |
| Hortobagyi, GN | 2 |
| Craft, A | 1 |
| Cotterill, S | 1 |
| Malcolm, A | 1 |
| Spooner, D | 2 |
| Grimer, R | 2 |
| Souhami, R | 1 |
| Imeson, J | 1 |
| Lewis, I | 2 |
| Comandone, A | 1 |
| Leone, L | 1 |
| Oliva, C | 1 |
| Frustaci, S | 1 |
| Monteleone, M | 1 |
| Colussi, AM | 1 |
| Dal Canton, O | 1 |
| Bergnolo, P | 1 |
| Boglione, A | 1 |
| Bumma, C | 1 |
| Huober, J | 1 |
| Schneeweiss, A | 1 |
| Hohaus, S | 1 |
| Wittmann, G | 1 |
| Meyer, A | 1 |
| Martin, S | 1 |
| Goldschmidt, H | 1 |
| Bastert, G | 1 |
| Haas, R | 1 |
| Wallwiener, D | 1 |
| Prince, HM | 2 |
| Gardyn, J | 1 |
| Rischin, D | 2 |
| Francis, P | 2 |
| Gates, P | 2 |
| Chapple, P | 2 |
| Quinn, M | 2 |
| Juneja, S | 2 |
| Wolf, M | 2 |
| Januszewicz, EH | 2 |
| Richardson, G | 2 |
| Scarlett, J | 2 |
| Briggs, P | 2 |
| Brettell, M | 2 |
| Toner, GC | 2 |
| Blakey, D | 1 |
| Seymour, JF | 1 |
| Strickland, A | 1 |
| Zalcberg, J | 1 |
| Bearman, S | 1 |
| Vredenburgh, J | 1 |
| Cagnoni, P | 1 |
| Shpall, E | 1 |
| Ross, M | 1 |
| Peters, W | 1 |
| Jones, R | 2 |
| Beyer, J | 1 |
| Einhorn, L | 2 |
| Nichols, C | 1 |
| Perey, L | 1 |
| Rosti, G | 1 |
| Lange, A | 1 |
| Pampallona, S | 1 |
| Peters, R | 1 |
| Humblet, Y | 1 |
| Bosquée, L | 1 |
| Pasini, F | 1 |
| Marangolo, M | 1 |
| Aziz, Z | 1 |
| Rehman, A | 1 |
| Qazi, S | 1 |
| Lobo, F | 1 |
| Frau, A | 1 |
| Barnadas, A | 1 |
| Méndez, M | 1 |
| Lizón, J | 1 |
| Provencio, M | 1 |
| Albistur, JJ | 1 |
| Martínez, P | 1 |
| Sánchez, MJ | 1 |
| Constenla, M | 1 |
| Estévez, LG | 1 |
| Chang, AY | 1 |
| Hui, L | 1 |
| Asbury, R | 1 |
| Boros, L | 1 |
| Garrow, G | 1 |
| Rubins, J | 1 |
| Hawkins, D | 1 |
| Pendergrass, T | 1 |
| Lindsley, K | 1 |
| Conrad, EU | 1 |
| Shankar, AG | 1 |
| Pinkerton, CR | 1 |
| Atra, A | 1 |
| Ashley, S | 1 |
| Cannon, S | 1 |
| Cotterill, SJ | 1 |
| Craft, AW | 1 |
| Chua, DT | 1 |
| Kwong, DL | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Choy, D | 1 |
| Edelman, MJ | 1 |
| Tsavaris, NB | 1 |
| Malamos, NA | 1 |
| Vadiaka, M | 1 |
| Koufos, C | 1 |
| Thurnher, D | 1 |
| Kornfehl, J | 1 |
| Burian, M | 1 |
| Gedlicka, C | 1 |
| Selzer, E | 1 |
| Quint, C | 1 |
| Neuchrist, C | 1 |
| Kornek, GV | 1 |
| Sreerama, L | 1 |
| Sládek, NE | 1 |
| Horibe, K | 1 |
| Fukuda, M | 1 |
| Miyajima, Y | 1 |
| Matsumoto, K | 1 |
| Kondo, M | 1 |
| Inaba, J | 1 |
| Miyashita, Y | 1 |
| Rixe, O | 1 |
| Köstler, WJ | 1 |
| Brodowicz, T | 1 |
| Attems, Y | 1 |
| Hejna, M | 1 |
| Tomek, S | 1 |
| Amann, G | 1 |
| Fiebiger, WC | 1 |
| Wiltschke, CH | 1 |
| Krainer, M | 1 |
| Zielinski, CC | 1 |
| Sandler, E | 1 |
| Lyden, E | 2 |
| Ruymann, F | 1 |
| Maurer, H | 1 |
| Wharam, M | 2 |
| Parham, D | 1 |
| Link, M | 2 |
| Crist, W | 1 |
| Pectasides, D | 1 |
| Kiamouris, C | 1 |
| Bafaloukos, D | 2 |
| Xiros, N | 1 |
| Nicolaides, C | 1 |
| Visvikis, A | 1 |
| Bernstein, M | 1 |
| Ferguson, W | 1 |
| Devidas, M | 1 |
| Siegal, GP | 1 |
| Schwartz, CL | 1 |
| Breitfeld, PP | 1 |
| Raney, RB | 1 |
| Teot, LA | 1 |
| Lobe, T | 1 |
| Crist, WM | 1 |
| Maurer, HM | 1 |
| Ruymann, FB | 1 |
| von der Maase, H | 1 |
| Seo, JH | 1 |
| Whang, YM | 1 |
| Kim, BS | 1 |
| Choi, CW | 1 |
| Shin, SW | 1 |
| Kim, YH | 1 |
| Kim, JS | 1 |
| Goo, BH | 1 |
| Sarris, K | 1 |
| Kalofonos, C | 1 |
| Gika, D | 1 |
| Gourgoulis, GM | 1 |
| Efstathiou, E | 1 |
| Skarlos, D | 1 |
| Körner, F | 2 |
| Lund, S | 1 |
| Jonas, U | 1 |
| Buzdar, AU | 1 |
| Legha, SS | 1 |
| Tashima, CK | 1 |
| Yap, HY | 1 |
| Hersh, EM | 1 |
| Blumenschein, GR | 1 |
| Bodey, GP | 1 |
| Schmidt, CG | 2 |
| Kokron, O | 3 |
| Titscher, R | 2 |
| Micksche, M | 1 |
| Cerni, C | 1 |
| Wrba, H | 1 |
| Neidhardt, B | 1 |
| Lutz, H | 1 |
| Corsi, A | 1 |
| Calabresi, F | 1 |
| Greco, C | 1 |
| Wicart, L | 1 |
| Loehrer, PJ | 1 |
| Rynard, S | 1 |
| Ansari, R | 1 |
| Songer, J | 1 |
| Pennington, K | 1 |
| Hawkins, RE | 1 |
| Schofield, JB | 1 |
| Wiltshaw, E | 2 |
| Fisher, C | 1 |
| McKinna, JA | 1 |
| Hirano, M | 1 |
| Okamoto, M | 1 |
| Maruyama, F | 1 |
| Ezaki, K | 1 |
| Shimizu, K | 1 |
| Ino, T | 1 |
| Matsui, T | 1 |
| Sobue, R | 1 |
| Shinkai, K | 1 |
| Zülfikar, B | 1 |
| Gedikoğlu, G | 1 |
| Gurney, H | 1 |
| de Campos, ES | 1 |
| Dodwell, D | 1 |
| Kamthan, A | 1 |
| Thatcher, N | 2 |
| Prendiville, J | 1 |
| Radford, J | 1 |
| Steward, W | 1 |
| Ranson, M | 1 |
| Burt, P | 1 |
| Stout, R | 1 |
| Lange, OF | 1 |
| Scheef, W | 2 |
| Haase, KD | 1 |
| Heckmann, M | 1 |
| Leyendecker, R | 1 |
| Urban, G | 1 |
| Zegners, G | 1 |
| Kok, TC | 1 |
| van der Gaast, A | 1 |
| Splinter, TA | 1 |
| Tilanus, HW | 1 |
| Weh, HJ | 1 |
| Zügel, M | 1 |
| Wingberg, D | 1 |
| Schwarz, R | 1 |
| Zornig, C | 1 |
| Dietel, M | 1 |
| Hossfeld, DK | 1 |
| Meier, W | 1 |
| Eiermann, W | 1 |
| Stieber, P | 1 |
| Fateh-Moghadam, A | 1 |
| Schneider, A | 1 |
| Hepp, H | 1 |
| Coleman, RE | 1 |
| Clarke, JM | 1 |
| Slevin, ML | 1 |
| Sweetenham, J | 1 |
| Williams, CJ | 1 |
| Blake, P | 1 |
| Calman, F | 1 |
| Harper, PG | 1 |
| Ghavamzadeh, A | 1 |
| Hoffmann, W | 1 |
| Weidmann, B | 1 |
| Migeod, F | 1 |
| Könner, J | 1 |
| Kaye, SB | 1 |
| Stoter, G | 1 |
| Sleijfer, D | 1 |
| Jones, W | 1 |
| Ten Bokkel Huinink, W | 1 |
| Splinter, T | 1 |
| Van Oosterom, A | 1 |
| Harris, A | 1 |
| Boven, E | 1 |
| De Pauw, M | 1 |
| Kurschel, E | 1 |
| Schilcher, RB | 1 |
| Weinhardt, O | 1 |
| Wandl, U | 1 |
| Thatcher, D | 1 |
| Lind, M | 1 |
| Morgenstern, G | 1 |
| Carr, T | 1 |
| Chadwick, G | 1 |
| Craig, P | 1 |
| Li, GC | 1 |
| Brock, N | 1 |
| Li, JQ | 1 |
| Negretti, E | 1 |
| Ferrari, L | 1 |
| Bonfante, V | 1 |
| Bajetta, E | 1 |
| Paprocka, M | 1 |
| Radzikowski, C | 1 |
| Einhorn, LH | 1 |
| Hoefer, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Risk-Adapted Strategy of the Use of Dose-Dense Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors[NCT00104676] | Phase 3 | 263 participants (Actual) | Interventional | 2003-11-26 | Active, not recruiting | ||
| High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors[NCT00936936] | Phase 2 | 64 participants (Actual) | Interventional | 2009-06-02 | Active, not recruiting | ||
| A Randomized Phase III Study of Sequential High-Dose Cisplatinum/Etoposide/Ifosfamide Plus Stem Cell Support Versus BEP in Patients With Poor Prognosis Germ Cell Cancer[NCT00003941] | Phase 3 | 222 participants (Anticipated) | Interventional | 1999-04-30 | Completed | ||
| Observational Study on Treatment of Skeletal Ewing Sarcoma at Diagnosis[NCT04845893] | 100 participants (Anticipated) | Observational | 2021-06-01 | Recruiting | |||
| A Multi-Centre Phase II Study Using Carboplatin AUC-10 for Metastatic Seminoma With IGCCCG Good Prognosis Disease-Therapy Directed by Initial Metabolic Response on PET-CT[NCT02272816] | Phase 2 | 48 participants (Actual) | Interventional | 2012-02-13 | Completed | ||
| A Phase II Trial In Which Patients With Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression[NCT01391962] | Phase 2 | 34 participants (Actual) | Interventional | 2011-07-18 | Active, not recruiting | ||
| Continuous 5 Days Infusion of High Dose Ifosfamide and Adriamycin in Patients With Advanced Sarcoma[NCT00002526] | Phase 2 | 20 participants (Actual) | Interventional | 1993-01-31 | Completed | ||
| PHASE I/II TRIAL OF SEQUENTIAL TAXOL/IFOSFAMIDE AND DOSEINTENSIVE CARBOPLATIN/ETOPOSIDE WITH STEM CELL SUPPORT IN CISPLATIN-RESISTANT GERM CELL TUMOR PATIENTS WITH UNFAVORABLE PROGNOSTIC FEATURES[NCT00002558] | Phase 1/Phase 2 | 108 participants (Actual) | Interventional | 1994-01-31 | Completed | ||
| Phase II Study of Cyclophosphamide, Doxorubicin, Vincristine, Etoposide, and Ifosfamide, Followed by Resection and Radiotherapy in Patients With Peripheral Primitive Neuroectodermal Tumors or Ewing's Sarcoma[NCT00002466] | Phase 2 | 0 participants | Interventional | 1990-05-31 | Completed | ||
| Endometrial Stromal Tumors: an Observational Study[NCT02829437] | 100 participants (Anticipated) | Observational | 2016-10-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluated the overall survival in both groups in participants presenting fast and slow decrease in serum levels of tumor markers. The median overall survival was defined as the median percentage of participants alive after 1 course of treatment. (NCT00104676)
Timeframe: 3 years from randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 65 |
| Arm II | 73 |
Primary objective is to compare the progression-free survival of participants after 1 cycle of treatment, treated randomly by 3 additional cycles of BEP (Arm I) or by T-BEP-Oxaliplatin/cisplatin-ifosfamide-Bleomycin (Arm II). The median progression-free survival rate was defined as the median percentage of participants alive without disease progression after 1 course of treatment. (NCT00104676)
Timeframe: 3 years from randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Arm I | 48 |
| Arm II | 59 |
Number of participants progression free 2 years after registration. (NCT02272816)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Carboplatin AUC-10 | 46 |
Overall Objective Response will be assessed prior to dose-intensive therapy and at the completion of therapy. Complete disappearance of all clinical, radiographic and biochemical (normal AFP and HCG) evidence of disease for a minimum of 4 weeks (CR to chemotherapy). Patients must be free of disease for a minimum of 4 weeks. Partial Response: Complete disappearance of all biochemical evidence of disease in patients without a surgical procedure for a residual radiographic mass. Patients must demonstrate no biochemical recurrence or progression of radiographic masses for a minimum of four weeks (PR to chemotherapy} (NCT00002558)
Timeframe: 2 years
| Intervention | participants (Number) | ||
|---|---|---|---|
| Complete Response (CR) | Incomplete Response (IR) | Partial Response (PR) | |
| Group A | 50 | 36 | 5 |
| Group B | 4 | 8 | 3 |
14 reviews available for ifosfamide and Metastase
| Article | Year |
|---|---|
Selection of Patients With Localized Extremity Soft Tissue Sarcoma for Treatment With Perioperative Chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; D | 2018 |
[Chemotherapy in male external genital organs (testicular and penile cancer)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin; Chemotherapy, Adjuvant; Cisp | 2013 |
An update on chemotherapy for osteosarcoma.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Clinical Tri | 2015 |
First-line treatment in advanced or metastatic disease: one size fits all or adapted to specific histiotypes?
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, | 2016 |
[Pleural epithelioid sarcoma: about a case and review of the literature].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fatal Outcome; Female; Humans; I | 2016 |
Salvage chemotherapy after failure of first-line chemotherapy in patients with metastatic testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Dose-Response R | 2008 |
[The guidelines for diagnostics and treatment of cervical cancer].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 2004 |
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas.
Topics: Adult; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Doxorubicin; Drug Thera | 2007 |
Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Humans; Ifosfam | 2008 |
High dose versus standard dose chemotherapy for the treatment of breast cancer. A review of current concepts.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carboplatin; Cycl | 1995 |
Paclitaxel combination therapy in the treatment of metastatic breast cancer.
Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 1996 |
New approaches to treatment of metastatic bladder cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothe | 2000 |
Current and future perspectives in advanced bladder cancer: is there a new standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogeni | 2002 |
Ifosfamide is an active drug for chemotherapy of metastatic cystosarcoma phyllodes.
Topics: Adult; Breast Neoplasms; Female; Humans; Ifosfamide; Mesna; Middle Aged; Neoplasm Metastasis; Phyllo | 1992 |
78 trials available for ifosfamide and Metastase
| Article | Year |
|---|---|
High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2014 |
Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively.
Topics: Administration, Inhalation; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; | 2016 |
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Topics: Adolescent; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomark | 2014 |
Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Chemotherap | 2014 |
Ifosfamide dose-intensification for patients with metastatic Ewing sarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Neoplasms; Child; Disease-Free Survival; | 2015 |
Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship | 2009 |
Chemotherapy: The role of ifosfamide and etoposide in Ewing sarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dactinomycin; Disease-Free Surviva | 2009 |
Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule | 2009 |
Phase I clinical and pharmacokinetic study of the glucose-conjugated cytotoxic agent D-19575 (glufosfamide) in patients with solid tumors.
Topics: Aged; Antineoplastic Agents; Female; Glucose; Humans; Ifosfamide; Infusions, Intravenous; Male; Midd | 2010 |
Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; H | 2010 |
Consolidation with high-dose chemotherapy and stem cell support for responding patients with metastatic soft tissue sarcomas: prospective, single-institutional phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Hemat | 2010 |
Prediction of chemotherapy outcome in patients with metastatic soft tissue sarcomas based on dynamic FDG PET (dPET) and a multiparameter analysis.
Topics: Discriminant Analysis; Doxorubicin; Drug Therapy, Combination; Fluorodeoxyglucose F18; Follow-Up Stu | 2010 |
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EO
Topics: Adolescent; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T | 2011 |
Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2011 |
No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Ifosfami | 2012 |
[Preliminary results of ifosfamide and doxorubicin regimen in treatment of patients with recurrent and metastatic nasopharyngeal carcinoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Humans; Ifosfamide; Male | 2002 |
GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell L | 2002 |
Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arm; Bone Neoplasms; Child; Child | 2003 |
[Effect of neoadjuvant chemotherapy in the treatment of patients with stage IIIB cervical cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Chemothe | 2003 |
Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: evaluation of combination ifosfamide and etoposide--a Children's Cancer Group and Pediatric Oncology Group study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 2004 |
Metastatic seminoma treated with either single agent carboplatin or cisplatin-based combination chemotherapy: a pooled analysis of two randomised trials.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carb | 2004 |
Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphami | 2005 |
Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Doxorubicin; Femal | 2006 |
Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, | 2006 |
Variations in schedules of ifosfamide administration: a better understanding of its implications on pharmacokinetics through a randomized cross-over study.
Topics: Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Cross-Over Studies; Drug Administration | 2007 |
Paclitaxel plus Ifosfamide followed by high-dose carboplatin plus etoposide in previously treated germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Surviva | 2007 |
Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 2007 |
Docetaxel-ifosfamide combination in patients with advanced breast cancer failing prior anthracycline-based regimens: results of a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Dose-Respo | 2007 |
Gemcitabine, ifosfamide and paclitaxel in advanced/metastatic non-small cell lung cancer patients: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycy | 2008 |
Salvage chemotherapy with mitomycin C, ifosfamide, and cisplatin (MIC) for previously treated metastatic or recurrent esophageal squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Di | 2008 |
Maintenance immunotherapy in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; CD4-CD8 Ratio | 2008 |
The use of granulocyte colony-stimulating factor to deliver four cycles of ifosfamide and epirubicin every 14 days in women with advanced or metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedul | 1995 |
Cyclosporin A and doxorubicin-ifosfamide in resistant solid tumours: a phase I and an immunological study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1995 |
Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 1995 |
Ifosfamide/carboplatin/etoposide chemotherapy for metastatic breast cancer with or without autologous hematopoietic stem cell transplantation: evaluation of dose-response relationships.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carbo | 1995 |
High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carb | 1995 |
Treatment of osteosarcoma with ifosfamide: comparison of response in pediatric patients with recurrent disease versus patients previously untreated: a Pediatric Oncology Group study.
Topics: Adolescent; Adult; Child; Clinical Trials, Phase II as Topic; Female; Humans; Ifosfamide; Male; Neop | 1995 |
A phase I/II study of a stepwise dose-escalated regimen of cisplatin, etoposide and ifosfamide plus granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with advanced germ cell tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Germinoma; Granulocyte-Macroph | 1993 |
Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1993 |
Evaluation of ifosfamide plus mesna as first-line chemotherapy in women with metastatic breast cancer.
Topics: Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Cystitis; Drug Administration Schedule; D | 1995 |
Ifosfamide treatment of recurrent or metastatic endometrial stromal sarcomas previously unexposed to chemotherapy: a study of the Gynecologic Oncology Group.
Topics: Antineoplastic Agents, Alkylating; Drug Administration Schedule; Endometrial Neoplasms; Female; Huma | 1996 |
Epirubicin and ifosfamide in metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; | 1996 |
Ifosfamide and vinorelbine as first-line chemotherapy for metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Humans; Ifosf | 1996 |
Dose-intense therapy with etoposide, ifosfamide, cisplatin, and epirubicin (VIP-E) in 100 consecutive patients with limited- and extensive-disease small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carc | 1997 |
Phase II study of vinorelbine and ifosfamide in anthracycline resistant metastatic breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1997 |
Cisplatin, ifosfamide, methotrexate and vinblastine combination chemotherapy for metastatic urothelial cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic A | 1997 |
Cisplatin and vinorelbine followed by ifosfamide plus epirubicin vs the opposite sequence in advanced unresectable stage III and metastatic stage IV non-small-cell lung cancer: a prospective randomized study of the Southern Italy Oncology Group (GOIM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1997 |
Recent advances in paclitaxel-containing chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1997 |
Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carc | 1998 |
Ifosfamide-based chemotherapy for previously treated lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcino | 1998 |
Phase II study of ifosfamide and mesna in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Breast Neoplasms; Female; Humans; Ifosfamide; Mesna; | 1998 |
Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Pre | 1998 |
Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Epirubicin; Fe | 1998 |
Ifosfamide in combination with paclitaxel or doxorubicin: regimens which effectively mobilize peripheral blood progenitor cells while demonstrating anti-tumor activity in patients with metastatic breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Breast Neoplasms; Combined | 1999 |
Repetitive high-dose therapy with ifosfamide, thiotepa and paclitaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Australia; Breast Neoplasms; Combined Modalit | 1999 |
Multiple courses of high-dose ifosfamide, carboplatin, and etoposide with peripheral-blood progenitor cells and filgrastim for small-cell lung cancer: A feasibility study by the European Group for Blood and Marrow Transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Dose- | 1999 |
Ifosfamide and vinorelbine in metastatic breast cancer in patients with prior anthracycline therapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asthenia; | 1999 |
Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neo | 1999 |
Ifosfamide, carboplatin and etoposide (ICE) in metastatic and refractory breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Drug Res | 1999 |
Very intensive, short-term chemotherapy for children and adolescents with metastatic sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Child; Child, Preschool; Cyc | 2000 |
A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-Up Studies; Huma | 2000 |
Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.
Topics: Actuarial Analysis; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell | 2001 |
Ifosfamide and mitoxantrone in the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, | 2001 |
Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Child; Child, Preschool; Disease Pro | 2001 |
Efficacy of ifosfamide and doxorubicin given as a phase II "window" in children with newly diagnosed metastatic rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Doxorubi | 2001 |
Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; He | 2001 |
Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Disease-Fr | 2002 |
Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: a report from the Intergroup Rhabdomyosarcoma Study Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bronchiolit | 2001 |
A Phase II study of paclitaxel by 24-hour infusion and ifosfamide in anthracycline-resistant metastatic breast carcinoma.
Topics: Adult; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Pro | 2002 |
Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progression; Drug Ad | 2002 |
Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination | 1979 |
[Clinical experiences with Holoxan in small cell carcinoma of the bronchus (author's transl)].
Topics: Bronchial Neoplasms; Carcinoma; Cyclophosphamide; Humans; Ifosfamide; Male; Neoplasm Metastasis; Qua | 1977 |
[Ifosfamide in the treatment of solid tumors and their metastases].
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Tolerance; Female; Humans; | 1976 |
Etoposide, ifosfamide, and cisplatin in extensive small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; | 1992 |
Palliative chemo-radiotherapy with ifosfamide and epirubicin as first-line treatment for high-risk metastatic breast cancer. Results of a prospective multicenter trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality The | 1990 |
Potential advances in combination chemotherapy for advanced testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Clinical Trials as Topic; Etop | 1988 |
[Treatment of oat cell metastazing bronchial carcinoma with isofosfamide. Results of a prospective randomized study].
Topics: Aged; Carcinoma, Small Cell; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Humans; If | 1974 |
[Treatment of bronchogenic cancer and lung metastases of solid tumors with ifosfamid (author's transl)].
Topics: Carcinoma, Bronchogenic; Clinical Trials as Topic; Cyclophosphamide; Drug Evaluation; Female; Humans | 1974 |
84 other studies available for ifosfamide and Metastase
| Article | Year |
|---|---|
Metastatic Malignant Peripheral Nerve Sheath Tumor With NF1 Successfully Treated With 'Gradual Subtraction' ICE Chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Humans; Ifosfamide; M | 2020 |
Epithelioid Hyalinizing Sarcoma With MGA-NUTM1 Fusion.
Topics: Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Cyclop | 2020 |
MTSS1 inhibits colorectal cancer metastasis by regulating the CXCR4/CXCL12 signaling axis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Chemokine CXCL12; Cisplatin; Colorectal Neo | 2021 |
Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Humans; Ifosfamid | 2017 |
FDG-PET/CT of invasive thymoma extending into the superior vena cava and right atrium.
Topics: Aged; Cisplatin; Fluorodeoxyglucose F18; Heart Atria; Humans; Ifosfamide; Male; Neoplasm Metastasis; | 2019 |
Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Doxorubicin; Female; Humans; Ifosfamide; Li | 2019 |
MAID chemotherapy regimen as a treatment strategy for metastatic malignant ameloblastoma: A case report.
Topics: Adult; Ameloblastoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; | 2019 |
Factors influencing survival in metastatic synovial sarcoma: importance of patterns of metastases and the first-line chemotherapy regimen.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Disease-Free Survival; Dox | 2013 |
ERCC1 expression does not predict survival and treatment response in advanced stage non-small cell lung cancer cases treated with platinum based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carb | 2013 |
Paclitaxel, ifosfamide, and cisplatin (TIP) as salvage and consolidation chemotherapy for advanced germ cell tumor.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Consolidation Chemotherapy; Drug R | 2015 |
Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Doce | 2015 |
Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplatin; Combined Modali | 2015 |
A trimodality approach in the management of metastatic low-grade epithelioid hemangioendothelioma of the bone.
Topics: Adult; Antineoplastic Agents; Bone Nails; Bone Neoplasms; Doxorubicin; Femur; Foot; Fracture Fixatio | 2015 |
Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; C | 2015 |
Adult Pleomorphic Rhabdomyosarcoma: A Multicentre Retrospective Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposi | 2015 |
Effective local control of advanced soft tissue sarcoma with neoadjuvant chemoradiotherapy and surgery: A single institutional experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Doxorubici | 2016 |
A single-centre analysis of 30 patients with relapsed germ cell tumours treated with the TI-CE regimen.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplati | 2016 |
Candidate germline polymorphisms of genes belonging to the pathways of four drugs used in osteosarcoma standard chemotherapy associated with risk, survival and toxicity in non-metastatic high-grade osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms | 2016 |
Myeloablative chemotherapy with autologous stem cell rescue for Ewing sarcoma.
Topics: Combined Modality Therapy; Etoposide; Humans; Ifosfamide; Myeloablative Agonists; Neoplasm Metastasi | 2008 |
Local and systemic control of Ewing's bone sarcoma family tumors of the ribs.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bone Plates; Chil | 2009 |
Evaluation of the paclitaxel-ifosfamide-cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans; Ifosfamide; | 2009 |
Paclitaxel combined with ifosfamide in anthracycline- and docetaxel-pretreated metastatic breast cancer: activity independence of prior docetaxel resistance.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docet | 2010 |
Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cisplati | 2011 |
Infratentorial brain metastases of pediatric non-epithelial malignant tumors: three case reports.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin | 2011 |
Novel approaches to treatment of leiomyosarcomas.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deox | 2011 |
Sequential or concomitant chemotherapy in limited stage small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Combined Modali | 2011 |
High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Bone Neoplasms; Disease-Free Survival; Female; Human | 2011 |
Maintenance therapy in the treatment of sarcoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Disease-Free Survival; Doxorubicin; Humans; Ifosfam | 2011 |
Primary metastatic Ewing's family tumors: results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation.
Topics: Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neopl | 2012 |
[Young man with severe back pain].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diagnosis, Differe | 2012 |
Evaluation of ifosfamide salvage therapy for metastatic canine osteosarcoma.
Topics: Amputation, Surgical; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemothera | 2014 |
Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2002 |
[Pediatric rhabdomyosarcoma of the infratemporal fossa].
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Co | 2002 |
A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; C | 2002 |
Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Topics: Adjuvants, Immunologic; Animals; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Cancer Vacci | 2003 |
[Primary pulmonary synovial sarcoma: a report and diagnosis of 2 cases].
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2003 |
Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Chil | 2003 |
Alveolar soft part sarcoma in Japan: multi-institutional study of 57 patients from the Japanese Musculoskeletal Oncology Group.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisp | 2003 |
Long-lasting complete remission of a patient with cervical cancer FIGO IVB treated by concomitant chemobrachyradiotherapy with ifosfamide and cisplatin and consolidation chemotherapy--a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; | 2004 |
Hypersensitivity pneumonitis associated with the use of trofosfamide.
Topics: Administration, Oral; Aged; Alveolitis, Extrinsic Allergic; Antineoplastic Combined Chemotherapy Pro | 2004 |
Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with Cisplatin-based chemotherapy.
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agen | 2004 |
Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Remodeling; Caspases; Cell Line, Tumor | 2005 |
Alveolar soft part sarcoma: a rare and enigmatic entity.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophos | 2005 |
Prognostic factors in pleuro-pulmonary blastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Adjuvant; Child; Child, P | 2007 |
[Comparing cisplatin plus etoposide with combination of mitomycin, ifosfamide and cisplatin in advanced non-small cell lung cancer patients].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Etoposide | 2006 |
[Preoperative adjuvant therapy for primary malignant bone tumors].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dactinomycin; Doxo | 2007 |
[A case of recurrent metastatic testicular cancer, successfully treated with paclitaxel, ifomide and cisplatin].
Topics: Adult; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic | 2008 |
Infectious complications from high-dose chemotherapy and autologous stem cell transplantation for metastatic germ cell tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Etoposide; Female; H | 2008 |
[Chemotherapy of metastatic renal cell carcinoma with cis-diamminedichloroplatinum and other drugs].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Renal Cell; Cispl | 1984 |
[Treatment of pain caused by metastases of reactivated prostatic cancer with ifosfamide].
Topics: Aged; Cyclophosphamide; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metast | 1983 |
[Combined cytostatic chemotherapy of advanced non-small-cell bronchial carcinoma with doxorubicin and ifosfamide].
Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophos | 1983 |
The value of ifosfamide in the polychemotherapy of metastasized testicular cancer pretreated with chemotherapy.
Topics: Adolescent; Adult; Alkylating Agents; Cisplatin; Cyclophosphamide; Drug Therapy, Combination; Humans | 1982 |
Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, | 1994 |
[Extraosseous Ewing's sarcoma].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dactinomycin; Diag | 1995 |
Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transplantation; Breast Neo | 1993 |
High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carboplatin; Com | 1995 |
Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Biot | 1998 |
High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Carmustine; Ci | 1999 |
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Controlled Clinical Trials as | 1999 |
Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neo | 1999 |
Primary breast tumor levels of suspected molecular determinants of cellular sensitivity to cyclophosphamide, ifosfamide, and certain other anticancer agents as predictors of paired metastatic tumor levels of these determinants. Rational individualization
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Antineoplastic Agents, Alkylating; Biomarke | 2001 |
Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Topics: Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Mar | 2001 |
[Concomitant radiochemotherapy for non-small-cell lung cancer: towards an ideal strategy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineopl | 2001 |
[Cytostatic therapy of tumors under conditions of partial synchronisation with particular reference to malignant tumors of the testicle (author's transl)].
Topics: Adult; Antineoplastic Agents; Bleomycin; Cell Transformation, Neoplastic; Child; Child, Preschool; D | 1975 |
Chemotherapy in testicular tumors.
Topics: Bleomycin; Castration; Cell Division; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; D | 1977 |
[Combined chemotherapy of metastasing melanoblastoma using ifosfamide and cis-platinum (II)-diamminodichloride (author's transl)].
Topics: Adult; Aged; Cisplatin; Cyclophosphamide; Female; Humans; Ifosfamide; Male; Melanoma; Middle Aged; N | 1979 |
[Clinical experiences with holoxan within the framework of sequential combination therapy (author's transl)].
Topics: Adult; Aged; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Hodgkin Disease; | 1978 |
Comparative effects of cyclophosphamide and isophosphamide on Lewis lung carcinoma.
Topics: Animals; Cyclophosphamide; Dose-Response Relationship, Drug; Ifosfamide; Lung Neoplasms; Mice; Neopl | 1978 |
Alternating non-cross-resistant chemotherapy for non-Hodgkin's lymphoma of intermediate-grade and high-grade malignancy. A pilot study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Cyclo | 1992 |
Ewing's sarcoma: experience with 12 cases.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Child, Preschool; | 1992 |
Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Sm | 1991 |
Intensive therapy for small-cell lung cancer using carboplatin alternating with cisplatin, ifosfamide, etoposide, mid-cycle vincristine, and radiotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Cis | 1991 |
Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group.
Topics: Adenocarcinoma; Adult; Aged; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Ifosfam | 1991 |
Chemotherapy of metastatic soft tissue sarcoma with a combination of adriamycin and DTIC or adriamycin and ifosfamide.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Dos | 1990 |
Squamous cell carcinoma antigen and carcinoembryonic antigen levels as prognostic factors for the response of cervical carcinoma to chemotherapy.
Topics: Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; | 1990 |
A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Dr | 1990 |
Treatment of metastatic breast cancer with the combination of ifosfamide, epirubicin and 5-fluorouracil.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Female; F | 1990 |
Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance; Epirubicin; Femal | 1990 |
Ifosfamide, methotrexate, and 5-fluorouracil in advanced pretreated breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Fluorouracil; | 1989 |
High-dose, double alkylating agent chemotherapy with DTIC, melphalan, or ifosfamide and marrow rescue for metastatic malignant melanoma.
Topics: Adult; Aged; Alkylating Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Ma | 1989 |
Treatment of advanced malignancies with ifosfamide under protection with mesna.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfamide; Male; Mesna | 1988 |
Phase II study with ifosfamide in advanced malignant melanoma.
Topics: Adult; Drug Evaluation; Humans; Ifosfamide; Melanoma; Middle Aged; Neoplasm Metastasis | 1988 |
Comparative studies on biological activity of /+/R and /-/S enantiomers of cyclophosphamide and ifosfamide. II. Antiproliferative activity of cyclophosphamide and ifosfamide enantiomers.
Topics: Animals; Cyclophosphamide; Ifosfamide; Leukemia P388; Leukemia, Experimental; Lung Neoplasms; Mice; | 1986 |
VP 16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Humans; Ifosfamide; Kidn | 1986 |